Tag: pharma

Abbott India Limited: Providing Quality Healthcare Solutions in India

Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations. Abbott India Ltd has approved the content in this post.

The character of the pharma industry is such that many people tend to think of it as a very different industry from the rest. It is perhaps one of the most developed sectors in recent times.

Talking about the pharmaceutical industry, Abbott Laboratories is one such company that has made a substantial global impact with its innovative pharma and medical products. Its global headquarters are present in Abbott Park, Illinois, United States. The company is spread across countries in Asia Pacific, Europe, the Middle East, South Africa, and the Americas. Founded in 1888 by Chicago medic Wallace Calvin Abbott, Abbott Laboratories has made a gigantic name for itself in India as well, with its subsidiary Abbott India Limited, which has its headquarters in Mumbai.

Dive into this article for further information on Abbott India Ltd. Read about its mission and vision, key products of Abbott India, business and revenue model, CSR activities, and more.

Abbott India Ltd. – Company Highlights

Company Name	Abbott India Limited
Headquarters	Mumbai, India
Sector	Pharmaceuticals, Healthcare
Type	Public
Founder	Wallace Calvin Abbott
Founded	1944
Parent Organisation	Abbott Laboratories
Website	abbott.co.in

Abbott India Ltd. – About

Abbott India Limited is a subsidiary of Abbott’s international pharmaceutical business in India. It is one of the country’s fastest-growing pharmaceutical firms today. Boots Pure Drug Company (India) Ltd was the initial name under which Abbott India Ltd was founded in 1944. It runs a production plant in Goa as well as a number of independent contractors and third-party producers located throughout the nation.

Abbott India Limited, an Abbott Laboratories subsidiary with its headquarters in Mumbai, offers reliable, high-quality medications in a variety of therapeutic areas, including women’s health, gastroenterology, cardiology, metabolic disorders, and primary care.

Abbott India Ltd is devoted to giving Indians access to high-quality healthcare through a combination of international and domestic goods. The company has its development and medical team that generates products and clinical trials that are specifically suited to the demands of the Indian market. Its staff members try to create high-quality, high-volume formulations utilizing methods that are economical. Additionally, Abbott’s skilled staff members are committed to guaranteeing adherence to global quality standards.

Some of Abbott’s well-known products include Pedialyte, Similac, BinaxNOW, Ensure, Glucerna, ZonePerfect, FreeStyle Libre, i-STAT, and MitraClip in the medical equipment, diagnostics, and nutrition product businesses.

Abbott India’s CSR Activities

Abbott India is also involved in many corporate social responsibility activities that focus the society in general.

Its therapy-shaping efforts are intended to enlighten and assist individuals in making educated decisions, dispel common misconceptions about illnesses, and increase accessibility and effectiveness. It has set up health clinics like Fibroscan and Liver clinics to help provide a quick, reliable, and timely diagnosis to people. Vaccination outreach programs to create awareness of flu. Abbott India has reached out to parents across more than 50 schools to create awareness and stress the importance of flu vaccines. More than 500 Menopause clinics were established pan India by Abbott India. The company has also executed around 100+ Pausetive Talks (awareness on menopause symptoms) for women across India in 12 regional languages, both digitally and physically.

Abbott India Ltd. – Industry details

India’s pharmaceutical sector is predicted to be worth $65 billion by 2024 and $130 billion by 2030. India’s pharmaceutical sector is currently worth $50 billion.

Patient expenditure on healthcare and medications is anticipated to increase for non-COVID-19 therapy as India’s economic growth is anticipated to continue.

Abbott India Ltd. – Founder and Team

Abbott India Ltd is the subsidiary of Abbott Laboratories, which was founded by Wallace Calvin Abbott in 1888.

Wallace Calvin Abbott

Dr. Wallace Calvin Abbott was born in 1857. He is a graduate of the University of Michigan. When he founded the Abbott Alkaloidal Company, Dr. Abbott was a practicing physician. He was one of the first American doctors to use a novel method to distill alkaloids, the components of medicinal plants that have a therapeutic effect into a solid form like morphine, quinine, strychnine, and codeine. This strategy was helpful because it gave patients more dependable and efficient dosing. The business relocated from Ravenswood to North Chicago, Illinois, in 1922.

Abbott Laboratories was one of the forerunners of the scientific practice of pharmacy under the visionary direction of Dr. Abbott, and it expanded to address increasing global health demands by supporting new fields of medical research.

Vivek V Kamath

Vivek V Kamath is the Managing Director of Abbott India Ltd. He has a degree in science with a focus on microbiology and a Master’s in Management with a focus on marketing. Mr. Vivek has more than 30 years of extensive and varied expertise in the healthcare industry, including the pharmaceutical, over-the-counter, and diagnostic industries. He has held many top leadership roles in reputable pharmaceutical firms, both Indian and MNCs, in a variety of geographical locations. Mr. Vivek also possesses significant functional knowledge in the fields of strategy, marketing, sales, and general management. He worked with MSD Pharmaceuticals, Roche Diagnostics in India, Novartis in Singapore, Ranbaxy, Pfizer in India, Fulford in India, Wockhardt, and Johnson & Johnson before joining Abbott.

Rajiv Sonalker

Rajiv Sonalker is the whole-time Director and CFO of Abbott India Ltd. He is a fellow member of the Institute of Chartered Accountants of India and holds a Bachelor’s Degree in Science from the University of Bombay. Rajiv Sonalker served as Director of Finance at Bristol-Myers Squibb before joining Abbott India. In Germany and India, Rajiv has also worked with Voltas Ltd., Johnson & Johnson, and Sanofi-Aventis.

Abbott India Ltd. – Startup Story | How It Began?

The story of Abbott India began in the 1940s. The origin of the company is when Dr. Wallace Calvin Abbott founded its parent organization Abbott Alkaloidal Company in 1888. It was during this time when the production of “alkaloidal” medicine granules was introduced, which made it a big hit in the market. After making sufficient sales in the USA, Abbott established its first overseas affiliate in London in 1907; the company then acquired a Montreal, Canada, affiliate. Boots Pure Drug Company (India) Ltd. was the initial name under which Abbott India Ltd. was formed on August 22, 1944. On November 1st, 1971, the business was renamed The Boots Company (India) Ltd; on January 1st, 1991, it became Boots Pharmaceuticals Ltd. The name was changed to Knoll Pharmaceuticals Ltd on October 31, 1995, and then to Abbott India Ltd on July 1, 2002.

17 new products were introduced by Abbott India during the fiscal year that concluded on March 31, 2016, and they collectively generated 1.9% of the company’s net sales. The firm and Bharat Biotech India Limited entered into a license agreement during the reviewed year to commercialize vaccines in the immunology category.

Abbott India Ltd. – Mission and Vision

The mission statement of Abbott India is, “to build life-changing technologies that keep your heart healthy, nourish your body at every stage of life, help you feel and move better, and bring you information, medicines, and breakthroughs to manage your health.”

Abbott India Ltd. – Name, Tagline, Logo

Abbott India Limited Logo

Before Abbott India, the company’s name was Knoll Pharmaceuticals Ltd. The name was changed in 2002.

The tagline of Abbott Laboratories is, “Live Your Best Life, Now And In The Future”

Abbott India Ltd. – Business Model

Diagnostics, medical equipment, branded generic drugs, and nutritional goods make up the core businesses of Abbott, which have been expanded via acquisitions. The company through its subsidiary, Abbott India creates and sells more than 600 goods for medical professionals that support Indians’ overall health and well-being.

The extensive pharmaceutical portfolio of Abbott in India covers the complete spectrum of healthcare requirements for all phases of life, from illness prevention to treatment and cure. Abbott Healthcare Solutions represents one of the largest pharmaceutical portfolios in India, including some of the market’s most dependable goods. In the fields of dermatology, diabetes, cardiology, gastrointestinal, central nervous system, pain management, and orthopedics, it is widely regarded as a market leader.

In India, the top of their respective categories is occupied by trademarks like Stemetil, Haemaccel, Kenacort, Paraxin, and Neomercazole. Abbott India’s business also includes providing high-quality healthcare to those living in ultra-urban areas where access to these quality healthcare solutions is a challenge. With a high-quality, reasonably priced portfolio of products in the therapy areas of pain management, gastroenterology, and anti-invectives for diseases like typhoid, malaria, and respiratory infections, Abbott True Care is assisting in improving the health and well-being of the people in extra-urban towns.

Abbott India’s main business operations are divided into the following categories:

Nutrition – This is further divided into categories like Adult Nutrition (Ensure and ZonePerfect), Child Nutrition (Isomil, and Gain) Infant Nutrition, and other medicinal nutrition
Diagnostics – with focus areas like Core labs, Molecular, and Point of Care
Established Pharmaceuticals – branded generic drugs
Medical devices – offering high-end medical devices for diabetic care, vascular care (coronary and endovascular), rhythm management, and electrophysiology.

The superior financial success has constantly been a result of the robustness of its business model.

Abbott India Ltd. – Revenue Model

Abbott India Ltd. made 11.4% of its Revenue from Operations. For FY 2021-2022, the company has delivered impressive results with 14.1% growth in revenue and 15.6% in net profits over the previous year. The company mostly generates its revenue from its diversified pharmaceutical portfolio.

Abbott India Ltd. – Growth

With a 14.1% growth in revenue (from ₹4,310 crores in FY21 to ₹4,919 crores in FY22), Abbott India has added 10 new items to its major portfolios in the therapeutic areas of women’s health, gastroenterology, central nervous system, multi-specialty, and vaccines. It conducts business in Nepal, Sri Lanka, Maldives, and Bhutan. Abbott India’s emphasis on expanding its business in these nearby nations and helping people through its high-quality products is also growing. It has a robust distribution network of more than 8,600 stockists and 60 lacs, retailers.

Abbott India Ltd. – Advertisements and Social Media Campaigns

In 2020, Abbott India launched the ‘Don’t Wait for Life’ campaign to highlight the importance of health challenges through technologies and solutions. The advertising campaign emphasizes the value of pursuing one’s dreams without sacrificing the life one is already living. The ad talks about Abbott’s groundbreaking cardiac pumps enabling people to continue living normally even when they have heart failure.

The campaign was launched by a series of four videos that depict the stability of people with heart problems and diabetes, which are considered highly prevalent non-communicable health conditions in India.

Abbott India Ltd. – Awards and Achievements

The list of awards and achievements won by Abbott India are:

Abbott India Ltd won the ‘GOLDEN PEACOCK HR EXCELLENCE AWARD’ For the second consecutive year from the Institute of Directors
Abbott India Ltd was recognized by Avatar and Working Mothers as the “Best Companies in India”
Abbott India Ltd won the “Best Places to Work” For 8 consecutive years by Business Today
Abbott India’s Goa plant received the prestigious Abbott Global EHS Excellence award for upgrading the fire-fighting facility without business interruption. The plant also received the Best Plant award from Abbott Global.

Abbott India Ltd. – Competitors

Abbott India competes with the following top competitors:

Torrent Pharma Success story: Making $1 Bn in Annual Revenue

Here’s the journey of how Torrent Pharma became the eighth biggest pharma company in India that manufactures and supplies products globally.

StartupTalkyShalini Rath

Abbott India Ltd. – Future Plans

Abbott India wants to keep placing a priority on developing novel medicines. The company further plans to introduce cutting-edge goods and services to the market. It believes this introduction is essential if it wants to revolutionize Indian healthcare.

FAQs

Who is the Managing Director of Abbott India Ltd.?

Mr. Vivek V Kamath is the Managing Director of Abbott India Ltd.

Is Abbott India Ltd a public company?

Yes, Abbott is a public company.

Where is the headquarters of Abbott India Ltd.?

The headquarter of Abbott India is in Mumbai.

April 8, 2023

Alkem Labs Success Story – India’s 5th Largest Pharma Company

Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations. The content in this post has been approved by Alkem Laboratories.

It can be safe to say that the importance of the pharmaceutical industry is increasing due to the increased need for pharmaceutical products. The pharmaceutical businesses are expandingly significantly these days. Therefore, every other pharmaceutical business is not backing down in offering high-quality pharma products.

This pharma company has been consistently expanding its geographic reach over the years. We are talking about India’s fifth largest pharmaceutical company in India in terms of domestic sales, Alkem Laboratories. It was founded in 1973 by an Indian businessman, Samprada Singh.

Read on to get a detailed understanding of Alkem Laboratories’ business and revenue model, its founder’s story, how it began its operations, its mission and vision, future goals, and more things in this article.

Alkem Laboratories – Company Highlights

Headquarters	Mumbai, India
Sector	Pharmaceuticals, Healthcare
Type	Public
Founder	Samprada Singh
Founded	1973
Revenue	Rs 10634.1 crores
Parent Organisation	Alkem Laboratories
Website	https://www.alkemlabs.com/

Alkem Laboratories – About | How it works?

Alkem Laboratories Ltd is a worldwide Indian pharmaceutical business with its headquarters in Mumbai, Maharashtra, India. It produces and markets pharmaceutical formulations, generic medications, and nutraceuticals both domestically and abroad.

The company has 21 production sites spread across several cities in India and the US. Leading regulatory agencies like the USFDA, MHRA SAHPRA TGA, WHO, TPD, NDA, MOH, and TFDA inspect and audit Alkem’s upper-crest facilities following cGMP guidelines.

Alkem Laboratories claims that it provides its products to more than 40 nations. The US is the company’s second-largest market after India. Australia, Chile, the Philippines, Kazakhstan, Europe, and East Africa are some of the other important markets. Modern production and R&D facilities located in the US and India support the company’s international activities and help to make high-quality healthcare products available, cheap, and accessible.

As mentioned earlier in terms of domestic sales, Alkem is the fifth-largest pharmaceutical firm in India. The company dominates the acute therapeutic market and is a rising force in the chronic therapeutic market. A strong sales and distribution network, as well as substantial brand-building and marketing initiatives, support Alkem’s India operations.

Alkem Laboratories is ranked in the third position in the Gastrointestinal and Analgesic therapy segments.

Alkem Laboratories’ CSR initiatives

Alkem’s primary goal is the “Go Green” initiative, which is to increase green cover through widespread planting.

Below this effort, the company has planted over a million trees in places that are prone to drought in India’s Maharashtra.

Conservation of water as well as trash management, are also important components of Alkem’s efforts to being an organization that is more sustainable.

Alkem also wants to thrive in EHS while establishing a long-lasting competitive business advantage. The EHS strategy is based on the company’s “Zero Harm” concept, which aims to prevent harm to people, property, and the environment. So far, around 19,916 EHS-related training have been conducted across manufacturing sites from the year (2021-2022). Alkem Laboratories also stresses the 3R principle: Reduce, Reuse, Recycle.

Alkem Laboratories – Industry details

As India is a major exporter of pharmaceuticals, its market is presently estimated at $50 billion. It is also projected that the global pharmaceutical industry market volume will reach $1,431.00 billion by 2027, with revenue predicted to expand at a pace of 5.23% per year (CAGR 2022–2027).

Alkem Laboratories – Founder and Team

Samprada Singh founded Alkem Laboratories in 1973.

Samprada Singh

Samprada Singh founded Alkem Laboratories along with his younger brother Basudeo Narayan Singh. He was born into a middle-class family that lived in the Bihar hamlet of Okri in the Jehanabad district. Agriculture provided the majority of his family’s income, although it was frequently destroyed by the wrath of nature. He served as the Chairman of Alkem Laboratories.

Samprada Singh got his Bachelor’s degree in Commerce from Patna University. He has won many accolades in his lifetime. To name a few; he received the Ernst and Young Entrepreneur of the Year in Healthcare and Life Sciences in 2017, Pharmaceutical Leadership Summit & Awards founded by Satya Brahma awarded Samprada Singh with a Lifetime Achievement Award in 2009. Samprada Singh was India’s 43rd richest person in 2017 as per Forbes magazine with an estimated net worth of $3.3 billion. Samprada Singh was aged 94 when he passed away on 27 July 2019 in Mumbai, India.

Basudeo Narayan Singh

Basudeo Narayan Singh is Alkem’s present Executive Chairman. He has worked in the Indian pharmaceutical sector for more than 40 years. At the 7th Annual Pharmaceutical Leadership Summit and the Pharma Leaders Business Leadership Awards in 2014, he was named “Business Leader of the Year.” Basudeo N. Singh had a stint as President of the Indian Drug Manufacturers’ Association. In 2016, he was also recognized as the “EY Entrepreneur of the Year in Life Sciences.” He also received the Indian Drug Manufacturers’ Association’s “Chief Mentor of the Year” award in 2018.

Sandeep Singh

Sandeep Singh is the Managing Director of Alkem Laboratories. He has over 18 years of experience in the pharmaceutical industry. Sandeep Singh joined the Board of Directors in 2018, and since then, he looks after the domestic as well as the international operations of the company.

Sandeep Singh received the “Emerging Pharma Leader of 2016 Award” presented by Pharma Leaders in collaboration with the Ministry of Health & Family Affairs, Government of India in 2016. He was also highlighted by “ET AND SPENCER STUART 40 under 40” in the year 2021.

Alkem Laboratories – Startup Story

Samprada Singh always wanted to be a doctor but fate had other plans for him. He established a medical supply store in 1953, and Laxmi Pharma, a pharmaceutical distribution business, followed six years later. Thereafter, Samprada Singh founded Magadh Pharma in Patna, his own pharmaceutical distribution business. After 16 years in distribution, he decided to join Aristo Labs in 1970 and got into pharmaceutical manufacturing. However, following a string of failures and failed alliances, he finally made a bold move that irrevocably altered the Indian Pharmaceutical Market, it was Alkem Laboratories.

The company began its successful journey in 1973. Alkem Laboratories’ first manufacturing unit was established at Taloja near Mumbai in 1978.

It was in 1992, that Alkem’s second production plant was developed in Gujarat’s Mandva, which later became an API facility in 2005.

Alkem Laboratories opened its first R&D center for ANDA at Taloja in the year 2003. In terms of domestic sales in India, the anti-infective medicine Taxim of Alkem became the first anti-infective to reach $1 billion in 2006 in the Indian pharmaceutical business. In terms of domestic sales in India, Clavam, another medication from Alkem, surpassed the 2,000 million milestones in 2014.

The business submitted its first ANDA for the medication Amlodipine in 2007, and it was authorized in 2009. In the six months that concluded on September 30, 2015, Alkem has created a portfolio of 705 branded generic pharmaceuticals, 13 of which were included among the top 300 brands in India for the fiscal year 2015.

Alkem Laboratories – Mission and Vision

The vision statement of Alkem is, “To achieve value-driven leadership in the Indian Healthcare Industry and beyond through: Quality that is infinite, Service that cares, and Hard work that endures.”

Alkem’s motivation derives from wanting to improve medical results. It remains committed to making significant contributions to healthcare that will improve the quality of life for people by enabling them to live longer, better-quality lives. It does this by leveraging its strong industry experience, robust quality standards, and demonstrated capabilities in research, manufacturing, and distribution.

Alkem Laboratories – Name, Tagline, Logo

The tagline of Alkem Laboratories is, “Four decades of empowering wellness”

Alkem Laboratories – Business Model

The business model of Alkem Laboratories includes developing, manufacturing, and marketing high-quality pharmaceutical products across all major therapeutic segments. It has more than 800+ brands out of which 12 brands have annual sales of more than Rs 1 crores.

Alkem’s multi-product portfolio has the following categories:

Generic Drugs
Active Pharmaceutical Ingredients (APIs)
Nutraceuticals
Biosimilars
Pharma products for Therapeutic Areas – like Anti-infective, Gastroenterology, Pain Relief/Analgesic, Anti-diabetic, Cardiology, Dermatology, Neurology/Central Nervous System, and Vitamins, Minerals & Nutrients.
OTC Products – Playgard condoms, Pregnancy detection kits, Livoerb (ayurvedic medicine)

Alkem’s six R&D centers are empowered with more than 500 scientists. The company operates its business in 19 manufacturing facilities. It is also present in more than 50 countries.

Here is the list of Alkem’s research facilities, which are located mainly in India and the USA:

Alkem Research Centre, Taloja, Navi Mumbai, Maharashtra
Alkem Research Centre, Mandva, Gujrat
Enzene Biosciences Limited, T-Block, MIDC, Bhosari, Pune, Maharashtra
Enzene Biosciences Limited, MIDC, Bhosari, Pimpri-Chinchwad, Pune, Maharashtra
Alkem Laboratories, Fenton, MO, USA
Norac Pharma, Azusa, CA, USA

International regulatory agencies, such as the US FDA, and European, Australian, and other authorities, have audited and authorized Alkem’s R&D centers.

Alkem Laboratories – Revenue Model

Alkem Laboratories’ revenue for this year was reported to be Rs 10,634.1 crores ($1.3 billion).

Alkem Laboratories generates 70.8% of its revenue in India, 21.9% from the USA, and the rest 7.3% from other international markets. The company makes about 32% of its total income from offshore sales.

Alkem Laboratories – Growth

Alkem Laboratories reports having a record of solid performance with a growth of 29.9% this year. The company’s both prescription business and trade generic business performed strongly, indicating that this increase was broad-based. According to a research study, Alkem increased by 27.6% compared to the Indian Pharmaceutical Market’s (IPM) rise of 18.2%. The company’s overall performance was boosted by robust volume growth in its acute treatment sectors, which was assisted in part by COVID-19 tailwinds.

Alkem Laboratories – Funding and Investors

Alkem Laboratories has raised a total of $60 million in funding over one round. It raised funds through a Venture – Series Unknown round. The company is backed by five investors. Its most recent investors are DB International and Kuwait Investment Authority. The other three investors of Alkem are; Apax Group, Morgan Stanley, and Abu Dhabi Investment Authority.

Alkem Laboratories – Investments

Till now, two investments are made by Alkem Laboratories. It recently invested in a Bangalore-based cell therapy company, Eyestem for Rs 510 crores.

Headquarters	Mumbai, India
Sector	Medical devices, Pharmaceuticals, Healthcare
Type	Public
Founder	Wallace Calvin Abbott
Founded	1944
Valuation	Rs 37,288.17 crores
Revenue	Rs 4,996.48 crores
Parent Organisation	Abbott Laboratories
Website	www.abbott.co.in

Alkem Laboratories – Mergers and Acquisitions

Below are some of the acquisitions made by Alkem Laboratories are:

Acquired Enzene Biosciences, a company engaged in the development of biosimilars in India (2011)
Acquired Ascend Laboratories, a pharmaceutical company in the US (2010)
Acquired Pharmacor Pty. Ltd., a generic pharmaceutical company in Australia (2009)
Acquired a formulation manufacturing facility in the US (2015)
Acquired the ‘Clindac-A’ brand in India from Galderma S.A. (2014)
Acquired an API manufacturing facility in the US (2012)

Alkem Laboratories – Advertisements and Social Media Campaigns

In 2016, Alkem Laboratories launched its first campaign for its ayurvedic product ‘Livoerb’ with the tagline ‘Rakho apne Liver ko mazboot aur jawaan’. The campaign highlights the importance of using Alkem’s product Livoerb that keeps the liver in a healthy condition.

The video shows an Indian family where a daughter-in-law is seen complaining about her in-laws’ unlimited demands of tasty food and how it is not affecting their health at this age. In the end, they reveal their secret to their daughter-in-law; that is by consuming ‘Livoerb’, which helps in regulating the functions of the liver.

Alkem Laboratories – Awards and Achievements

Here is the list of awards and achievements won by Alkem Laboratories:

2021

Alkem Laboratories won Great Place to Work Certified consecutively for the second time in a row

Alkem was recognized as India’s Best Workplace in Biotechnology & Pharmaceutical industry for the second consecutive year

2020

Achieved the CIO Conclave and Awards 2020 in the category Best IT Team of the Year

2019

Received the Express Pharma Excellence Award at Pharma CXO Summit 2019

Alkem received the Best Employee Engagement Practice and Best L&D Strategy Titles

2018

Alkem’s Brand ‘Clavam’ received the Brand of the Year 2018 Award at AWACS Awards for Marketing Excellence

Achieved the Best Innovative CSR Project at CSR Summit & Awards 2018

Alkem received the Business Excellence Award 2018 for Best Range of ICU Products, Pharma, and Health Care Summit organized by CMS.

Alkem Laboratories – Competitors

Alkem Laboratories has the following competitors:

Alkem Laboratories – Future Plans

Alkem Laboratories made spectacular growth of 29.9% as compared to the previous year. The company expects that its Chronic portfolio is getting better and better, expanding over two times as quickly as the market. Alkem’s recently established Pulmocare business, which serves the respiratory market, also had a successful debut. It believes that this new launch will also show a great growth rate of therapies.

FAQs

Who leads the company Alkem Laboratories?

The company is headed by Mr. Basudeo N Singh who is the Executive Chairman.

What is the rank of Alkem Laboratories?

Alkem Laboratories is the sixth-largest pharma company in India in terms of domestic sales.

Is Alkem an MNC?

Yes, Alkem Laboratories is an Indian Multinational pharma company.

Where is the headquarter of Alkem Laboratories?

The headquarter of Alkem is in Mumbai.

November 27, 2022

Intas Pharmaceuticals Limited – A Pharma Company from Ahmedabad Serving Global Markets

Pharmaceuticals are known to treat illnesses since time immemorial. In the early days, the treatments were very different than the ones we have right now. Today, new methods of development and innovative minds have made the pharmaceutical industry a million-dollar global industry.

Pharmaceutical manufacturing companies help boost the economy of the country. It has also greatly contributed to the ecosystem on a global level.

Intas Pharmaceuticals Limited is one such private pharmaceutical manufacturing company that is engaged in the formulation, manufacturing, and marketing of pharmaceuticals with its headquarters in Ahmedabad, Gujarat.

Uncover all the details of Instas Pharmaceuticals’s successful journey. Know about its founder, its key products, its business model, revenue, funding and investors, and so on.

Intas Pharmaceuticals Limited – Company Highlights

Company Name	Intas Pharmaceuticals
Headquarters	Ahmedabad, Gujarat, India
Sector	Pharmaceuticals
Type	Private
Founder	Hasmukh Chudgar
Founded	1977
Revenue	$2.2 billion
Website	intaspharma.com

Intas Pharmaceuticals Limited – About

Founded in 1977, one of the top international firms for the creation, production, and marketing of pharmaceutical formulations is Intas Pharmaceuticals. It is the largest privately held Indian generic pharma firm and is now rated ninth in the Indian pharmaceutical industry. Intas has established itself as a pioneer in India’s CNS, Cardio, Diabeto, Gastro, Urology, and Oncology therapeutic areas. It is renowned for its variety of products in the US and EU hospital-based therapeutic areas.

The company claims that over the last five years, it has grown at a rate of roughly 25.5% CAGR, and in the most recent fiscal year, it surpassed the $1.9 billion threshold.

13 of the company’s 19 production sites are located in India, 5 are in the United Kingdom, and 1 is in Mexico. Intas Pharmaceuticals has established a new production facility in Bavla, close to Ahmedabad, called PHARMEZ, with the ability to produce and export more than 1 billion solid doses and 5 million injectables.

Under the name Accord Healthcare, Intas has established a network of subsidiaries throughout the EU, US, Canada, SA, Australia, APAC, CIS, and MENA.

A commitment to delivering inexpensive biosimilars for billions across specialized categories including cancer, auto-immunity, ophthalmology, nephrology, rheumatology, and hormone-based medicines drives Intas’ highly developed EU-GMP Certified Biopharma division.

Intas Pharmaceuticals Limited – Industry Details

According to reports, the Indian pharma industry has witnessed a growth of 103% since 2014. The high economic growth is pushing the expenditure on healthcare and medicine. The reports say the industry will be around $50 billion by 2025.

Intas Pharmaceuticals Limited – Founder

Intas Pharmaceuticals is founded by Hasmukh Chudgar in 1977.

Hasmukh Chudgar

Hasmukh Chudgar graduated from Gujarat University with a degree in pharmacy. He is presently the Chairman of the company. Hasmukh’s sons Binish, Nimish, and Urmish operate the company’s day-to-day management. Intas’s business has expanded under Hasmukh Chudgar’s direction both organically and via mergers and acquisitions. It is present in many treatment domains, including cardiovascular, diabetes, gynecology, respiratory care, and gastrointestinal.

Hasmukh Chudgar is known for his low-profile image and has over six decades of experience in the pharma industry. The estimated net worth of his and his family is $6.5 billion.

Binish Chudgar

Binish Chudgar is the Vice-Chairman and Managing Director of Intas Pharmaceuticals Limited and its subsidiary Accord Healthcare. He gained his MBA degree in Accounting and Finance from the SP Jain Institute of Management and Research. Mr. Chudgar is the man behind the company’s strategic growth and finance. He has played a key role in building Intas a “future-ready” organization since he is constantly considering “what next.”

Intas Pharmaceuticals Limited – Startup Story

The company was started around 1977 and incorporated in 1985. In the initial days, Intas Pharma had a slow beginning. Still, it gradually started to pick up the pace with its strategic planning and taking initiatives in the chronic therapeutic business, including neurology and psychiatry. Much after a few years, the company’s entry into the field of cancer, which has given it a significant footing in global markets, was a major break. The strength of Intas is its aptitude for seeing markets before rivals. In cancer and subsequently, infertility, it was successful in achieving this. The acquisitions with multinational companies especially in UK and Ireland, the company made a position for itself in the European market.

Intas Pharmaceuticals Limited – Mission and Vision

The mission statement of Intas is, “Contributing to better healthcare through innovation. Maximizing value for our stakeholders and customers.”

Intas Pharmaceuticals’s Vision is, “To continually set new benchmarks in global healthcare with the power of human expertise, innovative research, and advanced technology.”

Intas Pharmaceuticals Limited – Name, Tagline, Logo

The tagline of Intas Pharmaceuticals is, “Expressions for a Healthy Life”

Intas Pharmaceuticals Limited – Business & Revenue Model

Intas Pharmaceutical can be said to have a diversified business model. The company also has a B2B platform by acting as an active pharmaceutical licensor by supplying 140+ different finished products to 90+ partners in more than 50 countries. It operates as a vertically integrated global pharmaceutical formulation development, manufacturing, and marketing company.

Intas has set up its subsidiary, Accord Healthcare to operate in global markets. With a strong sales, marketing, and distribution infrastructure in regions including North America, Europe, Central & Latin America, Asia-Pacific, CIS, and MENA nations, it is presently active in more than 85 countries globally.

The company has a sizable prescriber base with comprehensive coverage of important specialties like neurologists, psychiatrists, cardiologists, diabetologists, consulting physicians, urologists, nephrologists, & oncologists. More than 2,50,000 medical professionals and 1,50,000 retail locations are serviced by a dedicated team of 6,000+ sales representatives in metro, semi-urban, and rural markets.

Here’s a brief about Intas’ Domestic & International business units and how it generates its revenue:

India

Intas, one of the fastest-growing Indian pharmaceutical giants, is now placed seventh in the Indian pharmaceutical industry, with a 3.1% market share. Intas has been routinely exceeding the Indian market with 15% growth thanks to a sustainable business plan. For an increased focus on brand development, its 8 Strategic Business Units use a multidivisional model with more than 40 marketing divisions that serve different treatment areas. Neurology, psychiatry, and cardiovascular therapies account for 50% of Intas’ total domestic revenue.

EMENA

Intas entered the top 3 players in the UK and Ireland generics market in 2016 by acquiring Actavis’ UK and Ireland business. Intas has 8,500+ products registered in the European market.

USA

Intas’ US operations, which have their headquarters in Durham, North Carolina, are currently bringing in about $350 million in revenue. Intas has continued to develop and enhance its rating year after year despite competition from lower prices and a consolidated client base.

Other Emerging Markets

With a diversified business model, Intas has its business operations present in Emerging markets in more than 20 countries including Brazil, South Africa, Mexico, and Australia. It is reported that Intas’s sustainable business model helped achieve a 20% CAGR growth rate. Brazil contributed around 36% of its revenue, Mexico – 25%, South Arica – 15%, Asia – 10%, Australia and New Zealand – 7%, and other countries & Peru – 4%.

Intas Pharmaceuticals Limited – Funding and Investors

Throughout 4 rounds, Intas Pharmaceuticals has raised a total of $306.5M in investment. On June 2, 2020, they received their most recent round of investment from the secondary market. Two investors are funding Intas Pharmaceuticals. The most recent investors are Capital Group and Chrys Capital.

Date	Acquiree name
January 19, 2018	Bio-Pharm
August 1, 2016	Glochem – manufacturing unit
May 5, 2015	ZYG Pharma
December 13, 2013	Elder Pharmaceuticals
June 27, 2005	Excella GmbH

Intas Pharmaceuticals Limited – Mergers and Acquisitions

Two businesses have been bought by Intas Pharmaceuticals. Actavis Ireland Ltd. was their most recent purchase, made on October 6, 2016.

The second acquisition was made on October 5, 2016, when Intas Pharmaceuticals acquired Actavis UK Ltd., a UK-based supplier of generic pharmaceuticals. The amount details are undisclosed.

There are reports that Intas’s subsidiary, Accord Healthcare had acquired a company. Sanofi’s Fawdon factory in the UK was reopened in 2018 by Accord Healthcare to produce generic effervescent drugs. After Sanofi shuttered the operation, the factory was bought in 2015. Alongside, Harrow, Barnstaple, Haverhill, and Didcot, this is Accord’s sixth manufacturing facility in the nation.

Intas Pharmaceuticals Limited – Partnership

A new therapeutic option for prostate cancer patients in Europe is now available thanks to an exclusive licensing deal that Intas Pharmaceuticals Ltd’s subsidiary, Accord Healthcare Ltd, has signed with UK-based biotech company Myovant Sciences.

Through this partnership, the treatment of advanced hormone-sensitive prostate cancer under the brand Orgovyx (relugolix, 120 mg) will be available in the European Economic Area, the UK, Switzerland, and Turkey. As per the deal, Myovant Sciences will receive a total payment of $90.5 million. Intas-arm Accord will be in charge of regional commercialization and local clinical development, and it has the option to produce relugolix in the future.

Intas Pharmaceuticals Limited – Challenges/Controversies

In 2020, Intas Pharmaceuticals was accused of selling diabetes medications without first getting the National Pharmaceutical Pricing Authority pricing clearance.

Intas Pharmaceuticals Limited – Awards and Achievements

Here is the list of awards won by Intas Pharmaceuticals are:

Intas Pharma won the EY Entrepreneur of the Year award – in 2018
Intas Pharma has received ‘Express Pharma Excellence Awards 2019
Intas has won ‘Global Generics & Biosimilars Awards 2018’ – Biosimilar Initiative of the Year
Intas has won ‘Global Generics & Biosimilars Awards 2018’ – Company of the Year
Intas has won ‘Global Generics & Biosimilars Awards 2018’ – Company of the Year Asia-Pacific
Intas has won Gold & Silver Awards for ‘New Introduction of the Year’ at AWACS Awards in Marketing Excellence for its Rejunex CD3 product

Intas Pharmaceuticals Limited – Competitors

Intas competes with the following top companies:

Intas Pharmaceuticals Limited – Future Plans

Intas Pharmaceuticals is planning to acquire Athenex Inc in a $200-$250 million deal. Intas Pharmaceutical is competing with Dr. Reddy’s Laboratories, as the company is also planning to acquire Athenex. Athenex is a US-based global biopharmaceutical company, that plans to sell a majority of its stake.

FAQs

Who is the CEO of Intas Pharmaceuticals?

Nimish Chudgar is the CEO of Intas Pharmaceuticals.

Is Intas Pharmaceuticals an MNC?

Yes, Intas in an MNC.

What is the rank of Intas in the Indian market?

Intas currently ranked as the 10th biggest pharma company in India.

November 8, 2022

Mankind Pharma Limited – Success Story of the company behind some of the most popular pharma products

One of the most thriving industries of today is pharmaceuticals. This industry can be said to be one of the biggest industries that yield effective solutions for the countless health disorders we have in the world these days.

Pharmaceutical manufacturing is a booming business and stands out as one of the important domains in the world of medicine and drugs.

One such giant pharmaceutical company in India is Mankind Pharma, whose products have crossed the borders of India and have obtained quite a popularity. Mankind Pharma was founded in 1995 by Ramesh C. Juneja and Rajeev Juneja, with its main office located in New Delhi. The company also has a wide spectrum of products in the OTC and FMCG sector, apart from the pharmacy.

Mankind Pharma – Company Highlights

Headquarters	New Delhi, India
Sector	Pharmaceutical
Type	Private
Founder	Ramesh C. Juneja and Rajeev Juneja
Founded	1995
Areas served	worldwide
Revenue	INR 7500 Crores (2022)
Total Funding Raised	$239 million
Website	mankindpharma.com

Mankind Pharma – About

Mankind Pharma is an Indian global pharma company that offers therapeutic goods in a variety of categories, including antibiotics, gastrointestinal, cardiovascular, dermal, and erectile dysfunction drugs. They span industrial fields including labs, medicines, and medical research.

The company has three major brands; Manforce, Prega News, and Gas-O-Fast.

Mankind is India’s fourth-largest pharmaceutical company by domestic sales. It mostly focuses on delivering quality products at affordable prices and maintains a record of building and scaling brands in-house. Around 34 foreign countries in Asia, Africa, South-East Asia, the Gulf of Mexico, and the CIS is where Mankind conducts its business.

The pharma has three R&D centers located in IMT Manesar, Gurugram, and Haryana.

Mankind Pharma – Industry details

The Pharma industry is probably one of the crucial industries to enhance the quality of our life. Today, the Indian Pharmaceutical industry is estimated to be worth $42 billion worldwide.

Mankind Pharma – Founder

Mankind Pharma is founded by two brothers Ramesh C. Juneja and Rajeev Juneja in 1995.

Ramesh C. Juneja

Ramesh. C. Juneja has honorable positions in several Indian pharmaceutical organizations. He is currently the Chairperson of Mankind Pharma. Ramesh C. Juneja began his career in 1974 with KeePharma Ltd. as a medical representative after earning his degree in science. He started working for Lupin Limited in 1975 and held the position of first-line manager for about 8 years. Ramesh C. Juneja serves as the head of the Himachal Pradesh-UK State Board for the Indian Drug Manufacturers Association and the Federation of Pharma Entrepreneurs (FOPE).

Network 18 presented Ramesh C. Juneja with the Business Icon Pharma Award in 2011. He was also one of the four business titans nominated for the 2012 Asia Business Leadership Award and the 5th Annual Pharmaceutical Leadership Summit’s “Business Leader of the Year Award.” According to Forbes‘ list of the Top 100 Richest Indians, Ramesh C. Juneja is one of the richest Indians in September 2013.

Rajeev Juneja

Rajeev Juneja co-founded Mankind Pharma Limited along with his brother Ramesh C. Juneja. Presently, Rajeev Juneja serves as the Vice-Chairman of the company. He dropped out of college to work in several pharmaceutical sectors before founding Mankind Pharma. Rajeev Juneja is the organization’s main motivator and the reason for its success. He provides Mankind Pharma with a competitive edge with his understanding of every facet of marketing. Rajeev’s goal is to make Mankind Pharma one of the top three businesses with a significant market share in the OTC and FMCG sectors.

Mankind Pharma – Startup Story

Mankind Pharma was officially formed in 1991 but eventually started its business operations in 1995. In the initial days, Mankind Pharma had raised just Rs 50 lakhs through seed funding.

In the 2000s, Mankind Pharma produced many breakthrough pharma products. In 2004, it launched the ‘Amlokind’ tablets and ‘Glimestar’ tablets. The following year, it opened its first manufacturing facility at Paonta, Himachal Pradesh.

The medicine Dydrogesterone, also known by the brand name Dydroboon and used in high-risk pregnancies, was developed and released by Mankind in 2019, making it the first Indian business to do so and the second in the world overall.

Mankind now employs over 14,000 people and aims toward $1 billion in sales.

Mankind Pharma – Mission and Vision

The vision of Mankind Pharma is, “To be a global pharmaceutical company, most admired for its Affordability, Quality, and Accessibility of products.”

Mankind Pharma’s mission statement reads, “To be able to provide cost-effective, innovation-based superior quality pharmaceutical products across the globe, to improve the lives of the patients.”

Mankind Pharma strongly believes in and follows its seven Core Values:

Customer Centricity
Quality
Innovation
Integrity
Go Beyond
People Development and Collaboration

Mankind Pharma – Business & Revenue Model

Mankind Pharma’s business operations mostly involve manufacturing APIs, Therapeutics categories like dermal, antibiotics, cardiovascular, anti-diabetics, vitamins, minerals, nutrients, and other generic medications. Along with the three main R&D centers, Mankind has two additional R&D centers, which are managed by its non-wholly owned subsidiaries. This includes its COPMED Research Centre in Dehradun, Uttrakhand, and Mediforce Research Centre at Paonta Sahib, Himachal Pradesh.

Mankind Pharma’s business includes producing several differentiated brands of condoms, oral contraceptives, antacids, pregnancy detection, anti-acne gels and creams, and vitamin and mineral supplements.

Mankind generates its main source of revenue by selling its following brands, which are also some of its highest-selling pharmaceutical brands. These are:

Dydroboon
Manforce
Unwanted-Kit
Prega News
Nurokind-LC
Codistar
Telmikind
Cefakind

Mankind Pharma reports generating about 97% of its revenue through domestic sales. It also generates a good amount of income in the chronic therapeutic areas.

Mankind Pharma’s CSR activities

The company also operates by supporting many non-profit organizations that are engaged in education, healthcare facilities, social welfare, conservation of natural resources, and rural development.

Mankind Pharma – Funding and Investors

Over two rounds, Mankind Pharma has raised total funds of $239 million. On May 28, 2015, they received their most recent round of finance from the secondary market. Three investors have financed Mankind Pharma. Capital Group and Chrys Capital are its most recent investors. The company is also reported to have been funded by an American-based independent investment firm, HarbourVest Partners.

Date	Funding Round	Amount	Investors
May 28, 2015	Secondary Market	$215 million	Capital Group
April 30, 2007	Private Equity Round	$24 million	Chrys Capital

Mankind Pharma – Mergers and Acquisition

On February 1, 2022, Mankind Pharma bought Panacea Biotec Pharma’s Formulations division. For $19.1 billion, they purchased Panacea Biotec Pharma’s Formulations division.

Mankind Pharma – Investments

Until now, Mankind Pharma has made three investments. Leverage Edu raised $22 million on March 21, 2022, marking their most recent investment. Leverage Edu is a marketplace powered by AI that is intended to assist students with their objectives for further education and job advancement.

Date	Organization Name	Amount Invested
March 21, 2022	Leverage Edu	$22 million
January 19, 2022	Dogsee Chew	$500 million
August 11, 2021	Miko	$2.1 billion

Mankind Pharma – Advertisements and Social Media Campaigns

Mankind Pharma has always been a player in marketing its brand like no other company. The company has roped in several Bollywood stars to endorse its brands and reach a massive target audience.

In August 2021, Mankind Pharma launched a campaign to spread awareness about the essence of Covid vaccination. The campaign was called ‘Vaccinate My India’. The video shows a doctor holding a torch and further handing it over to other frontline workers like pharmacists, nurses, delivery agents, ambulance drivers, police, army officials, and every other person to highlight the message of vaccination to beat the virus.

Here is what Rajeev Juneja, the MD, and Vice-Chairperson of Mankind Pharma said regarding the campaign, “As the leaders in the pharmaceutical industry, our communication is always in alignment with the betterment and safety of our nation. With this campaign, we want to educate each and every citizen with regard to the importance of vaccination. Vaccinations are our only mode of protection from the deadly virus and we all must actively ensure to get as many people as possible vaccinated.”

Mankind Pharma – Awards and Achievements

Mankind Pharma has won several awards. Some of these awards are listed below:
In 2022:

Best of Bharat Awards by exchange4media
Mankind won the Award for Branding and Excellence for the Strategic Initiative to introduce DMF Quality Drugs in India

In 2021:

Mankind received Silver Medal from National Awards for Manufacturing Competitiveness Assessment
Sliver Award for Good Health Brand

In 2018:

Mankind Pharma got the Best Condom Brand of the Year Award
Pharma OTC Company of the Year Award

In 2017:

Mankind Pharma received the Award for Best Design in Healthcare

Mankind Pharma – Competitors

The list of top competitors of Mankind Pharma are:

Cipla
Lupin
Dabur
Sun Pharmaceuticals
Dr. Reddy’s Lab
Divi’s Laboratories
Torrent Pharma
Abbott India
Raymond’s brand Kamasutra
Syngene International
Biological E
Novo Nordisk

Mankind Pharma – Future Plans

As per recent reports, Mankind Pharma has piled up many future plans. It is planning to enter the capital market by the end of 2022 with a target of a $1 billion IPO. Besides this, it is also aiming to launch more products in anti-diabetics and cardiovascular areas in the coming months. It also wants to focus on acquiring vaccine companies. Mankind Pharma wants to expand its operations beyond India, by establishing in the USA market with an ambition to achieve around Rs 600 crore annually.

FAQs

Who is the CEO of Mankind?

Sheetal Arora is the current CEO of Mankind.

Is Mankind Pharma a private company?

Mankind Pharma is a public unlisted company.

Where is the head office of Mankind Pharma?

Mankind Pharma has its head office in New Delhi.

What is the ranking of Mankind Pharma in the Indian pharmaceutical market?

Based on overall revenue, Mankind Pharma is India’s 10 largest pharma company.

November 8, 2022

The Success Story of Torrent Pharma becoming a drug manufacturing giant

Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations. Torrent Pharma has approved the content in this post.

Diseases and medications have been an essential part of our lives since the dawn of time. The human body has health issues, and with the fast-paced lifestyle today, it is increasing like anything. Heart problems, diabetes, and blood pressure are some of the common diseases in today’s world. These issues are on the rise, and so is the pharmaceutical industry.

Pharma industries have become an integral part of our lives. This particular industry has a huge social responsibility while creating pharma products. One such well-known company like Torrent Pharmaceuticals Ltd. deals mainly in manufacturing drugs for Cardiovascular, nervous system (CNS), gastrointestinal, diabetes, etc. It was founded in 1959 by Indian businessman Uttambhai Nathalal Mehta.

Get all the details we have covered about Torrent Pharmaceuticals in this article. Learn about Torrent Pharmaceuticals’s business strategy, its products, the startup story, funding and investors, and more.

Torrent Pharma – About

Torrent Pharma, the flagship company of the Torrent Group, is one of the country’s leading pharmaceutical enterprises. As per records, it ranks eighth in the Indian Pharma Market and is in the top five in the therapeutic areas of Cardiovascular, Central Nervous System, Gastrointestinal, and Vitamins Minerals Nutritionals. Other than being present in these therapeutic areas, the company has a strong presence in diabetology, pain management, gynecology, cancer, and anti-infective industries.

Torrent Pharma has eight production sites, out of which 7 are in India and 1 in the United States, five of which are FDA-approved. It has invested heavily in R&D capabilities, with state-of-the-art R&D infrastructure employing over 700 scientists, as the backbone for its expansion in the local and international markets.

Today, the company has a presence in over 40 countries and is ranked first among Indian pharmaceutical companies in Brazil, Germany, and the Philippines.

Torrent Pharma – Company Highlights

Date	Funding Round	Fund Amount	Investors
January 7, 2021	Venture Round	₹5.6 billion	ADQ
November 9, 2020	Private Equity Round	₹11.3 billion	Goldman Sachs
July 31, 2020	Private Equity Round	₹2.3 billion	Tata Capital
January 6, 2020	Private Equity Round	₹5.4 billion	True North

Torrent Pharma – Industry details

The high rise of numerous diseases is resulting in the improvement of the healthcare sector these days. According to a report, the worldwide pharmaceutical manufacturing market is estimated to be worth $957.59 billion by 2028, which is growing at a CAGR of 11.34%.

Torrent Pharma – Founder

Uttambhai Nathalal Mehta is the founder of Torrent Group. Torrent Pharmaceuticals is the flagship company of the Torrent Group.

Uttambhai Nathalal Mehta

U.N Mehta was born in Mehmadpur, a tiny hamlet in India’s Palanpur district in 1924. While living at the Mahavir Jain Vidyalay hostel, he earned his B.Sc. from Wilson College. He began his career as a government servant. From 1945 through 1958, he worked as a medical representative for the pharmaceutical corporation Sandoz.

It was in 1959, that U.N Mehta made the ground-breaking decision to establish his own company, Trinity Laboratories, with a starting capital of only Rs 25,000. This organization began producing specialized medications. It was a significant move at a period when only multinational corporations produced specialty medications, and Mr. Mehta went on to found Torrent Laboratories in 1976. The firm began promoting a variety of important pharmaceuticals at extremely lower rates and quickly established a reputation for itself. Torrent is now a huge corporation involved in pharmaceuticals and electricity generation.

U.N Mehta is commemorated by the U. N. Mehta Institute of Cardiology and Research Centre (UNMICRC) in Ahmedabad, Gujarat. He received various honors, including the Government of India’s ‘Business Man of the Year’ award in 1996-97. He is also known for his philanthropic contributions and has also financially supported social, educational, and humanitarian institutions and causes.

U.N Mehta was married to Shardaben Mehta. They have four children: two sons, Sudhir Mehta and Samir Mehta, and two daughters, Meena and Nayna. He left for the heavenly abode in 1998 in Ahmedabad.

Samir Uttamlal Mehta

Samir Uttamlal Mehta along with his brother Sudhir Mehta run the business of the Torrent Group. Samir has a master’s degree in business administration from the B.K. School of Business Management. Torrent Pharma took several strategic initiatives under his leadership, including ventures into novel therapeutic and geographies, large investments in product development infrastructure and capabilities, building state-of-the-art manufacturing facilities, and acquisitions, establishing Torrent as one of India’s fastest-growing and most respected Pharma companies.

Samit Mehta is responsible for the Group’s entry into the burgeoning City Gas Distribution sector by participating in bidding rounds for new territories and acquiring existing CGD firms to increase its commercial footprint.

Sudhir Uttamlal Mehta

Sudhir Uttamlal Mehta joined the family business in the early 70s. He has a bachelor’s degree from Gujarat University. Mr. Mehta joined his father in handling the activities of Torrent Pharma after finishing his schooling and began studying the complexities of business and management under his father’s guidance. He contributed significant dynamism and business acumen to the Group, culminating in the first success of Torrent Pharma, the Torrent Group’s flagship firm.

Torrent Pharma – Startup Story

The actual story of Torrent Pharmaceuticals began in 1971 as a Private Limited Company by Shri Rajnikant C. Patel and his family members. Later on, it was acquired by U.N Mehta. The Company’s primary business was the production of pharmaceutical formulations and bulk pharmaceuticals. The Company’s products had a strong reputation and were highly recognized in the market from that time.

On 28th June 1989, the Company became a deemed Public Company under the provisions of Section 43-A of the Act and by a Special, Resolution passed on 25th July 1992 at the Annual General Meeting, the Company became a Public Limited Company within the meaning of Section 3(1)(iv) of the act and adopted a new set of articles.

Fast forward to 1994, in the Indian market, the company was the first to introduce ranitidine (Ranitin), nifedipine (Calcigard), atenolol (Betacard), domperidone (Domstal), diltiazem (Dilzem), amiodorane (Cordarone), lisinopril (Listril), and other medications. During the same year, the Company introduced many new medications, including Zirtin, Tyklid, Flutamide, and Topcef, all of which were favorably welcomed by the market. In 1997, the firm made strategic agreements with world-renowned pharmaceutical companies such as Sanofi in France for cardio-vascular products and Novo Nordisk in Denmark for diabetes treatment. With sales in over 70 countries and a network of international marketing offices, Torrent become one of India’s top exporters of medicinal formulations during that period.

All these years, the contributions by Torrent Pharmaceuticals were many. Recently, the company launched MSD (a brand name of Merck & Co., Inc, Kenilworth, NJ, USA) and Ridgebacks molnupiravir under the brand name Molnutor.

Torrent Pharma – Mission and Vision

Torrent Pharma’s mission statement is, “We commit ourselves to total customer care by delivering world-class products and services.”

The vision statement is, “To become the Most Respected Pharma Company.”

The company strongly believes in its Core values upon which it ensures longevity. Its core values are:

Integrity
Passion for Excellence,
Participative Decision Making,
Concern for Society & Environment,
Fairness with Care and Transparency.

Torrent Pharma – Name, Tagline, Logo

The tagline of Torrent Pharma is, “Innovating For A Healthier Tomorrow”

Torrent Pharma – Business & Revenue Model

Torrent Pharma’s business can be divided into three main segments:

India Business

The company has established itself as a prominent participant in the Indian Pharma field, from pioneering specialized marketing in India to earning the moniker “The Company with the Most First Launches.” They have well-separated marketing divisions that are strategically oriented toward distinct therapeutic sectors. Furthermore, it has a dominant position in the therapeutic segments of the cardiovascular, central nervous system, gastrointestinal, and women’s healthcare as mentioned earlier.

The company’s main areas of focus include formulations, API, drug discovery, marketing, and drug sales. Its operational manufacturing & R&D sites are as follows:

The manufacturing plant at Dahej, Gujarat
The manufacturing plant at Pithampur, Madhya Pradesh
Research Centre, Ahmedabad-Gandhinagar region, Gujarat – R & D Centre is spread out over 125,000 Sq. mts. with a built-up area of 41,000 Sq. mts.
The manufacturing plant at Indrad, Mehsana, Gujarat
The manufacturing plant at Baddi, Himachal Pradesh
Corporate Office, besides sales India, off. Ashram Road, [Ahmedabad]- Gujarat
The manufacturing plant at Visakhapatnam (Andhra Pradesh)
3 Manufacturing plant at Rang-Po, (Sikkim)

International Business

Torrent Pharma has its operations in the EU territory. It has operational sites are present in Germany, UK, and Brazil. The company is also an emerging market in countries like Russia, CIS, South East Asia, Asia Pacific, Africa, the Middle East, Australia, and Central and Latin America.

Torrent Pharma is present in African Countries like Kenya, Zimbabwe, Nigeria, Uganda, and South Africa. In Asian countries like – Sri Lanka, Malaysia, Philippines, Vietnam, and Myanmar.

US Business

Torrent has expanded its business footprint in the United States with the acquisition of Bio-Pharm, Inc. (BPI), a generic medicines and over-the-counter (OTC) company situated in Levittown, Pennsylvania. Torrent Pharma Inc., our subsidiary, meets the expanding market demand for our medicines, and we are now rated 10th among US generic Indian companies.

Approximately 85% of the Company’s revenue originates from four key markets: India, the United States, Germany, and Brazil. Torrent Pharma’s business mix (70% BGx and 30% Gx) is highly optimized since it blends steady financial returns with operational leverage and cost competitiveness.

Torrent Pharma’s CSR Activities

Torrent Pharma believes in the philosophy of “Think of others also when you think about yourself”. Through this principle, Torrent Pharma makes ongoing efforts through its CSR initiatives to give back to society for all of the care, healing, support, and nourishment bestowed on us. Its CSR initiatives are:

Community Health care, Sanitation, and Hygiene – Some of the projects are – the U.N.Mehta Institute of Cardiology and Research Centre (UNMICRC), Swadhar, the Community Health Care Centre, and REACH – the Paediatric Healthcare Programme
Education and Knowledge Enhancement – Set up many schools such as – Sharda Mandir Primary School, K.G. Mehta High School, Akhakhol Primary School, and Shiksha Setu: A Teaching-Learning Enhancement Programme in 2011.
Social Care and Concern – Urja Dweep, is a green-power residential complex situated at SUGEN Plant, Surat.

Torrent Pharma – Revenue Growth

Torrent Pharma’s EBITDA margins were 31% (2020-21 32%). Margins were greater the prior year due to Covid-induced cost moderation. Current-year margins were impacted by pricing pressures in the US base business, as well as a lack of fresh releases pending USFDA re-inspection of facilities.

The company reported having a revenue of $1.1 billion in 2022.

Torrent Pharma – Funding and Investors

Torrent Pharmaceuticals has received $40 million in investment in one round. On April 3, 2014, a Post-IPO Equity round was raised. Chrys Capital, an investment firm focused in India, is the company, which has invested in Torrent Pharmaceuticals.

Torrent Pharma – Mergers and Acquisitions

Torrent Pharmaceuticals has acquired five companies. Bio-Pharm was their most recent purchase, which occurred on January 19, 2018.

Date	Funding Round	Fund Amount	Investors
January 7, 2021	Venture Round	₹5.6 billion	ADQ
November 9, 2020	Private Equity Round	₹11.3 billion	Goldman Sachs
July 31, 2020	Private Equity Round	₹2.3 billion	Tata Capital
January 6, 2020	Private Equity Round	₹5.4 billion	True North

Recently, Dr. Reddy’s Laboratories Ltd. has made an agreement with Torrent Pharma to buy four of its brands: “Styptovit-E,” “Finast,” “Finast-T,” and “Dynapress.”

Torrent Pharma – Awards and Achievements

Torrent Pharma has won many awards such as:

It was listed amongst the top five ‘Fastest Growing Companies (Middleweights Category)’ by Business World Magazine – in 2017
Torrent Pharma’s manufacturing plant in Dahej, received USFDA approval – in 2016
Torrent Pharma was recognized as the Most Promising Company of the Year at the 10th CNBC TV18 India Business Leader Awards 2014

Milestones

Torrent Pharma entered into a licensing agreement with Medicine Patent Pool to manufacture and commercialize a generic version of Pfizer Oral COVID-19 Treatment
Torrent Pharma Entered Into Voluntary Licensing Agreement with Lilly to manufacture and distribute Baricitinib for Covid-19 in India – 2021

Torrent Pharma – Competitors

Torrent Pharma competes with the following companies:

Torrent Pharma – Future Plans

Torrent Pharma plans to stay dedicated to remaining patient-centric, delivering best-in-class performance metrics, and driving portfolio innovation in order to achieve above-market growth. The company is anticipating that the US will contribute favorably to the Company’s total growth following facility re-inspection, which will be assisted by new product releases.

FAQs

Who is the founder of Torrent Pharma?

U.N. Mehta is the founder of Torrent Pharma.

What is the rank of Torrent Pharma in India?

In India, Torrent pharma ranks as the 8th biggest pharma company.

Where is Torrent pharma based?

Torrent Pharma is based in Ahmedabad.

October 29, 2022

Innovexia Life Sciences Pvt. Ltd. | Success Story of becoming a prominent player in the Indian pharma industry

Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations. The content in this post has been approved by Innovexia Life Sciences Pvt. Ltd.

From the 19th century onwards, the world saw how pharmaceutical science improved remarkably. It was during that period when the pharmaceutical industry witnessed some major developments in new classes of pharmaceuticals. Scientists and biologists worked hard to make prominent progress with their in-depth research to create some of the vital drugs that many of us are familiar with today.

Innovexia Life Sciences Pvt. Ltd. was established in 2011, that produces, trades distributes, and supplies a large variety of pharmaceutical medicines and injections. It is also regarded as one of the leading pharmaceutical franchise companies in Chandigarh.

Let us find out more about Life Sciences Innovexia Pvt. Ltd’s success story, its founder, the type of business model they have, how it generates its revenue, and so on.

Innovexia Life Sciences Pvt. Ltd. – Company Highlights

Headquarters	Chandigarh, India
Sector	Pharmaceutical manufacturing
Type	Private
Founder	Sandeep Khajuria
Founded	2011
Revenue	Rs 100 crores (approximately)
Website	www.innovexia.com

Innovexia Life Sciences Pvt. Ltd. – About
Innovexia Life Sciences Pvt. Ltd. – Industry Details
Innovexia Life Sciences Pvt. Ltd. – Founder
Innovexia Life Sciences Pvt. Ltd. – Mission and Vision
Innovexia Life Sciences Pvt. Ltd. – Name, Tagline, Logo
Innovexia Life Sciences Pvt. Ltd. – Business & Revenue Model
Innovexia Life Sciences Pvt. Ltd. – Award & Achievement
Innovexia Life Sciences Pvt. Ltd. – Competitors
Innovexia Life Sciences Pvt. Ltd. – Future Plans

Innovexia Life Sciences Pvt. Ltd. – About

The Innovexia Life Sciences Pvt. Ltd is a pharma company that is engaged in offering a wide variety of products ranging from advanced antibiotics, high-quality vitamins, minerals, protein, chemicals, and other materials. The company is also engaged in the services of marketing a wide range of medicines under the business segment – the PCD Pharma franchise. Innovexia also offers contract manufacturing services to various clients to help them in the smooth functioning of the business. It deals in manufacturing products like tablets, capsules, derma range, ayurvedic products, herbal products, and many more at its technologically advanced manufacturing unit, which is GMP and WHO-approved. The company deals in brands like Duotime-S, Innoscab, Rightpro Plus, Innodent, and many more.

Innovexia Life Sciences is considered to be one of the emerging pharma companies in India.

Innovexia Life Sciences Pvt. Ltd. – Industry Details

In terms of quality manufacturing and value, the Indian Pharmaceutical industry comes at the 14th position. As per a survey, the domestic pharma market is anticipated to grow at least 3 times more in the coming years and is likely to reach $50-60 billion by 2025.

Innovexia Life Sciences Pvt. Ltd. – Founder

Innovexia Life Sciences is founded by Sandeep Khajuria.

Sandeep Khajuria

Sandeep Khajuria is presently the Chairman and Managing Director at Innovexia Life Sciences. He is a well-known and respected figure in the pharmaceutical sector. Mr. Sandeep Khajuria has more than 25 years of expertise in this field. He has worked in various sectors like Human Resources, Sales & Marketing, and Production & Distribution, at different levels in popular companies like Dr. Reddy’s Laboratories & Cipla Limited.

Innovexia Life Sciences Pvt. Ltd. – Mission and Vision

Innovexia Life Sciences’ mission statement is, “To become a leading Pharmaceutical Company in India in the sphere of excellence manufacturing, innovation, formulation, marketing and to escalate the business from the threshold of country and to become a forerunner in overseas.”

The company aims to improve the health of every person by offering its customers a wide range of pharmaceuticals.

Innovexia Life Sciences Pvt. Ltd. – Name, Tagline, Logo

The tagline of Innovexia Life Sciences is, “Life through Innovation”

Innovexia Life Sciences Pvt. Ltd. – Business & Revenue Model

Innovexia Life Sciences business involves offering three types of services – High-quality Pharma products, PCD Pharma Franchise, and Contract Manufacturing.

High-quality Pharma products

Innovexia manufactures some first-rate pharmaceutical products at affordable prices. All of its products have been certified by ISO, WHO, and GMP. It creates medicines and drugs for Dental, Gastro, Injections, Herbal, Nasal Spray, Pediatrics, Syrups, Lotions, Urology, Tablets, and Capsules.

PCD Pharma Franchise Business

Innovexia is also engaged in offering marketing solutions for pharma startups from across the country. The company seeks Pharmacy dealers, manufacturers, and distributors to become a part of the Pharma Franchise in Chandigarh. With this initiative, the company aims to open doors for other pharma startups to help them achieve substantial growth with a remarkable profit margin. Its key focus area is Allopathic PCD Pharma Franchise across India. The company also targets Baddi as its main location with the PCD Pharma Franchise in Baddi (Himachal Pradesh). Apart from these two locations, it is also looking for companies for District wise PCD Franchise in other states such as – Andhra Pradesh, Assam, Bihar, Bangalore, Chhattisgarh, Goa, Odisha, Gujarat, Rajasthan, Tamil Nadu, Kerela, Uttar Pradesh, Maharashtra, Madhya Pradesh, Tripura, Uttarakhand among many others.

Contract Manufacturing

Innovexia Life Sciences also takes up the manufacturing process of other companies. The company does its business with full transparency without any hidden costs. It also claims that its manufacturing units are well-equipped with the latest technology and machines to make sure that they deliver maximum output in a given time frame. Furthermore, the company also takes care of the packaging of its drugs. It uses quality packaging techniques so that the drugs are free from any damage. All in all, Innovexia Life Sciences focuses on every bit of the manufacturing process.

Innovexia generates its maximum revenue through the three services it offers. To be precise, the company gains through its contract manufacturing process as it is a market leader in the domestic contract manufacturing sector in the pharmaceutical industry.

Innovexia Life Sciences Pvt. Ltd. – Award & Achievement

Innovexia Life Sciences has won the following awards:

Innovexia Life Sciences has won the India 5000 Best MSME Award For Quality Excellence – 2020.
Innovexia Life Sciences received the IndiaMart TrustSeal certificate in 2013
Innovexia has been certified by ISO 9001: 2015 for Quality Management System
Innovexia Life Sciences was recognized by Indiamart for the ‘Leaders of Tomorrow Award.

Innovexia Life Sciences Pvt. Ltd. – Competitors

The list of top competitors of Innovexia Life Sciences are:

Innovexia Life Sciences Pvt. Ltd. – Future Plans

Innovexia Life Sciences is actively looking for pharma partners in other states besides Chandigarh and Baddi to expand its PCD Pharma Franchise Business. The company is always striving to improve the quality of its pharma products to enhance patient’s life with its innovative and effective products.

FAQs

Who is the CEO of Innovexia Life Sciences?

Sandeep Khajuria is the CEO of Innovexia Life Sciences.

Where is Innovexia Life Sciences based?

Innovexia Life Sciences is based in Chandigarh.

October 29, 2022

Laurus Labs Ltd. | How it became a top provider of APIs for international pharmaceutical firms

Pharmaceuticals are becoming an essential component of daily living. By saving people from the terrible grip of fatal illnesses, they are improving public health. The industry is growing each day, with various pharma companies indulging in developing new and innovative pharma products.

Laurus Labs Ltd. is an international pharmaceutical and biotechnology firm based in Hyderabad, India. It has three manufacturing units in Visakhapatnam, Hyderabad, and Bengaluru. Founded by Dr. Satyanarayana Chava, the pharma company focuses on creating APIs, custom synthesis, generic medications, and biotechnology. Laurus Labs is a top provider of APIs for international pharmaceutical firms operating all over the world in the ARV therapeutic arena.

Know all about Laurus Labs’ funding, founders, mergers and acquisitions, business and revenue model, how it started, marketing strategies, and more.

Laurus Labs – Company Highlights

Headquarters	Chandigarh, India
Sector	Pharmaceutical manufacturing
Type	Private
Founder	Sandeep Khajuria
Founded	2011
Revenue	Rs 100 crores (approximately)
Website	www.innovexia.com

Laurus Labs – About
Laurus Labs – Industry details
Laurus Labs – Founders and Team
Laurus Labs – Startup Story
Laurus Labs – Mission and Vision
Laurus Labs – Name, Tagline, Logo
Laurus Labs – Business & Revenue Model
Laurus Labs – Growth
Laurus Labs – Funding and Investors
Laurus Labs – Mergers and Acquisitions
Laurus Labs – Awards and Achievements
Laurus Labs – Competitors
Laurus Labs – Future Plans

Laurus Labs – About

The Hyderabad-based pharma company, Laurus Labs provides a wide range of integrated products and services to the worldwide pharmaceutical sector. With a top-notch infrastructure, top-notch staff, and a commitment to knowledge, innovation, and excellence, Laurus Labs quickly became a market leader in the production of high-quality APIs, a top choice for NCE development and manufacturing, and a reliable supplier of specialty ingredients for the nutraceutical sector. It offers its APIs in almost 56 countries. Furthermore, its main priority includes anti-retroviral, Hepatitis C, and Oncology drugs. API refers to the Active Pharmaceutical Ingredients that are used in medicines.

The company works with the top 10 generic pharmaceutical firms in the world. It has about 55+ cutting-edge R&D centers in India and US. In addition, it has more than 90 APIs manufactured at its 8 manufacturing facilities. Laurus Labs has more than 750 research scientists in their team of more than 4000 employees. It has received certification and approval from the WHO, USFDA, NIP Hungary, PMDA, KFDA, and BfArM for its facilities. Laurus Labs’ ability to manufacture APIs and conduct robust R&D has allowed them to expand quickly and globally.

Laurus Labs CSR activities

Following the provisions of the Companies Act of 2013 and the Companies (Corporate Social Responsibility) Rules of 2014, which were issued by the Central Government, Laurus Labs has implemented a Corporate Social Responsibility (“CSR”) policy. Its CSR efforts are generally concentrated on programs that support the environment, healthcare, and education, especially in the regions close to our industrial locations. The CSR Committee of its Board keeps an eye on all of its CSR initiatives. Laurus Labs’ Environmental, Social, and Governance (ESG) operations, which are a crucial component of its strategy and a significant reputation driver, also saw additional advancement. The ESG initiatives of Laurus Labs remained in the top 25% of global pharmaceutical businesses according to MSCI’s evaluation of ESG risk tolerance, with an “A” grade.

Laurus Labs – Industry details

The year 2020 has been a year of rapid change for the pharma industry and the world. Despite the challenges, the pharma industry is one of the crucial industries in the world that has been growing with each passing day. It is predicted that the industry’s market value will reach around $130 billion by 2030.

Laurus Labs – Founders and Team

Laurus Labs is founded by Dr. Satyanarayana Chava in 2005.

Dr. Satyanarayana Chava

Dr. Chave graduated from Andhra University with a science bachelor’s and master’s degree. From 1985 until 1992, he worked as a research scholar at the College of Science and Technology at Andhra University, where he later earned his Ph.D. He has been part of the company since January 21, 2006, as its Whole-Time Director. Besides, Dr. Chave is the CEO of Laurus Labs Ltd.

Vantaram Venkata Ravi Kumar

Mr. V V Ravi Kumar serves as Laurus’s executive, full-time director, and Chief Financial Officer. He has been a director of the firm since November 30, 2006. Mr. V V Ravi Kumar’s responsibilities include overseeing the finance and human resources departments as well as the supply chain management division for a sizable period.
Laurus Labs – Startup Story

Laurus Labs – Startup Story

Laurus Labs began its pharmaceutical journey by opening up its first R&D center in Hyderabad in 2005. Within four years, the company commenced its first international business by launching its first product in Europe. Thereafter, it entered into an agreement with an international organization to manufacture and sell its products in the ARV segment. From the 2010s onwards, Laurus Labs made some acquisitions to expand its operations.

Laurus Labs opened many more manufacturing facilities in and around Visakhapatnam, Hyderabad, and Bangalore. Today, the company has made a revenue of $48 billion and has three subsidiaries; Laurus Generics, Laurus Synthesis, and Laurus Bio.

Laurus Labs – Mission and Vision

Laurus Labs’ vision tells, “To become a leading player in offering integrated solutions to global pharmaceutical needs in creating a healthier world.”

The company aspires to offer affordable pharmaceutical products all over the world.

The mission statement of Laurus Labs reads, “We constantly strive for innovation to enhance quality and to provide affordable integrated pharmaceutical solutions to facilitate wellness and well-being across the globe.”

Laurus Labs – Name, Tagline, Logo

The tagline of Laurus Labs is, “Knowledge. Innovation. Excellence.”

Laurus Labs – Business & Revenue Model

Laurus Labs’ business operations are divided into four segments. These are; contract development and manufacturing (CDMO)-Synthesis, generic formulation (FDF), generic APIs, and biotechnology.

The company provides a wide range of integrated products and services to the international pharmaceutical sector. The culmination of its comprehensive approach which has been successfully carried out over these many years is the transition from APIs to formulations to synthesis enterprises. Throughout the whole value chain of the product, its four business units address a broad range of therapeutic uses.

Generic formulation (FDF)

The US Food and Drug Administration permitted Laurus Labs to sell hydroxychloroquine pills in March 2020. The business declared that it will provide hydroxychloroquine for COVID-19 prevention clinical studies. Some of the generic formulation products offered are:

Anti-retroviral, Anti-diabetic, Cardiovascular, Proton Pump Inhibitors, and Central nervous system. Generic formulation contributes about 38% of its revenue. FDF business increased 13% year over year to Rs 1,880 core. (FY21-22).

CDMO – Synthesis

Laurus Labs had a new CDMO multi-year cooperation agreement for specialized APIs signed with a top Global Lifesciences firm. The business’ CDMO division is called Laurus Synthesis. [15] The three most significant markets for Laurus Synthesis are the United States, the European Union, and Japan. Due to the acquisition of new clients and growing demand from current clients, the company’s CDMO business expanded steadily at 77% y-o-y. The CDMO-Synthesis business generates 19% of revenue for the company.

Generics – API

With one of the greatest HiPotent API capabilities in India, Laurus Labs claims to be the “world’s largest third-party API provider for antiretrovirals.” In addition, the business produces cancer and cardiovascular APIs, which Laurus Labs sells to nine of the top ten generic pharmaceutical firms worldwide. Generics- API business is the company’s highest source of revenue, with 41% revenue contribution.

Laurus Bio

The company’s biotechnology division is called Laurus Bio. By purchasing the Indian biotech firm Richcore in 2020, Laurus Labs entered the biotechnology industry. Laurus Labs provide novel protein companies and bio-manufacturers with comprehensive fermentation-based product development and manufacturing expertise, as a service (CDMO), including clone development, strain engineering, process development, scale-up, and large-scale commercial manufacturing. It further supports its customers at every stage of the microbial precision fermentation value chain. Revenues for 2021–22 increased significantly by over 70% over the pre-acquisition annualized run-rate, driven by appealing market possibilities. Laurus Bio recorded Rs 100 crores in sales. It contributes about 2% of the revenue for company.

Laurus Labs – Growth

In 2021–2022, the formulation division reported a 13% increase in sales to Rs 1,880 crores. Oncology API and other API sales also grew well, with a solid order book supporting a positive growth forecast. Since Laurus is a fully integrated participant in ARV formulations, it thinks it will be able to handle any price difficulties in the upcoming quarters. Laurus Labs’ revenue increased by 3% to Rs 4,936 crores. This happened because of the company’s strong FDF performance and exceptional CDMO business growth.

Laurus Labs – Funding and Investors

Over the course of 3 rounds, Laurus Labs has raised a total of $148.1 million in investment. Their most recent round of investment, a Post-IPO Equity round, was raised on December 6, 2016. Laurus Labs is funded by three investors. The three investors are; Goldman Sachs, Warburg Pincus, and Eight Roads Ventures.

Headquarters	Chandigarh, India
Sector	Pharmaceutical manufacturing
Type	Private
Founder	Sandeep Khajuria
Founded	2011
Revenue	Rs 100 crores (approximately)
Website	www.innovexia.com

Laurus Labs – Mergers and Acquisitions

Richcore was bought by Laurus Labs on November 26, 2020. Laurus Labs paid $2.5 billion to purchase Richcore. Richore is a Bangalore-based company that creates new enzyme applications for the food, water, and energy industries.

Laurus Labs – Awards and Achievements

Here’s the list of awards and achievements received by Laurus Labs are:

Emerging Company of the Year 2021 Awarded by Economic Times – Corporate Excellence Awards
E&Y Entrepreneur of the Year 2021 presented for Healthcare and Life Sciences segment
Laurus Labs received Great Place to Work For the third consecutive time in a study conducted by the Great Place to Work Institute (2021-2022)
Laurus Labs won the Business Person of the Year 2021 Awarded by Sakshi Excellence Awards
Great Place to Work Recognised Dr. Satyanarayana Chava, Founder & CEO as one of India’s best Leaders in Times of Crisis 2021

Laurus Labs – Competitors

Below is the list of top competitors of Laurs Labs:

Sun Pharma
Dr. Reddy’s Laboratories
Cipla Limited
Divi’s Laboratories
Aurobindo Pharma
Lupin
Torrent Pharma
Glenmark Pharma Limited
Abbott India
Zydus
Gland
Alkem Lab
Pfizer

Laurus Labs – Future Plans

By making investments in backward integration initiatives to build more API and FDF capacity in non-ARV infrastructure, Laurus Labs continues to fortify its position as a competitive integrated pharmaceutical company. Laurus Labs’ subsidiary Laurus Bio just finished a big expansion plan, it is anticipated that the company would see tremendous growth. It wants to increase Laurus Bio’s fermentation capacity by one million liters, which will be operational in 2023–2024 and have fuel growth in 2024–2025.

FAQs

Who is the CEO of Laurus Labs?

Satyanarayna Chava is the CEO of Laurus Labs.

What is the market cap of Laurus Labs in India?

The market cap of Laurus Labs is 30153.92 Crores.

Is Laurus Labs a public company?

Yes, Laurus Labs went public on December 6, 2016.

Where is Lausus Labs based?

Laurus Labs is based in Hyderabad.

October 23, 2022

Lupin Limited | Success Story of becoming a multinational pharma company
Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations. The content in this post has been approved by Lupin Limited.

The roots of the pharmaceutical industry come from the era of the 19th century. Knowing how traditional remedies were given based on folk knowledge is amusing. Slowly, the industry saw various developments of new classes of medicines manufactured by giant pharma companies.

Lupin Limited founded in 1968, is one such Indian multinational company that focuses on producing generic products in therapeutic areas including cardiovascular, diabetology, pediatrics, anti-infectives, asthma, and anti-tuberculosis.

If you’re interested to know how Lupic became a multination pharmaceutical company, then read this article to find out about its founders and team, its key products, its business model, how it generates its revenue, and many other details.

Lupin Limited – Company Highlights

Headquarters Mumbai

Type Private

Founder Desh Bandhu Gupta

Founded 1968

Revenue 15299.25 Crores- (FY2020-21)

Website www.lupin.com

About Lupin Limited
Lupin Limited – Industry details
Lupin Limited – Founder and Team
Lupin Limited – Startup Story
Lupin Limited – Mission and Vision
Lupin Limited – Name, Tagline, Logo
Lupin Limited – Business Model
Lupin Limited – Revenue Model
Lupin Limited – Funding and Investors
Lupin Limited – Mergers and Acquisitions
Lupin Limited – Advertisements and Social Media Campaigns
Lupin Limited – Awards and Achievements
Lupin Limited – Competitors
Lupin Limited – Future Plans

About Lupin Limited

Founded in 1968, Lupin Limited is an Indian global pharmaceutical corporation headquartered in Mumbai, Maharashtra. It offers Branded and Generic Formulations, Biosimilars, and Active Pharmaceutical Ingredients (APIs). It is one of the world’s largest generic pharmaceutical firms in terms of revenue. Presently, Lupin is the 6th Largest Indian Pharma as per Market Ranking.

The company is also a major player in the United States, India, and Japan, as well as other countries in APAC, EMEA, and LATAM. Besides this, it is a global market leader in the Anti-TB and Cephalosporin categories.

Lupin claims to employ almost 20,000 people in 11 countries on six continents, ensuring the safe and dependable supply of medications to patients in 100+ countries. It has 18 world-class production facilities that meet international standards scattered across India, Japan, the United States, Mexico, and Brazil. With seven R&D centers, the company has a powerful research and development team that has aided them in achieving leading positions in generics, complicated generics, APIs, biosimilars, and specialties.

The company has submitted 437 ANDAs (Abbreviated New Drug Applications), 45 first-to-files, and 289 ANDA approvals.

Lupin Limited – Industry details

The constant improvement in the areas of medicines and drugs with huge technological advancements has significantly impacted this space of the pharma industry. Due to this progress, it is anticipated that the pharma industry will see growth at a compound annual growth rate (CAGR) of 11.34% from 2021 to 2028.

Lupin Limited – Founder and Team

Lupin Limited is founded by Indian entrepreneur and billionaire Desh Bandhu Gupta.

Manju Gupta & Desh Bandhu Gupta

Desh Bandhu Gupta

Desh Bandhu Gupta was born in Alwar, Rajasthan 9 years before India got Independent. He had four siblings and was the oldest of them. Mr. Gupta had a master’s degree in chemistry from Bombay University. His career began as an associate professor at Rajasthan’s Birla Institute of Technology and Science in Pilani. But soon quit teaching and wanted to change and improve the healthcare sector in India.

It is told that Mr.Gupta created Lupin with a start-up capital of Rs 5,000 borrowed from his wife, Manju Gupta. He received an Ernst & Young Entrepreneur of the Year Award in the healthcare sector in 2011, as well as a Frost & Sullivan Lifetime Achievement Award in 2013. Mr. Gupta was also honored into the Hall of Fame posthumously at the CNBC TV18 India Business Leader Awards 2018.

Desh Bandhu Gupta died on June 26, 2017, at the age of 79, in Mumbai. He was married to Manju Gupta. They have five children; four daughters and one son. He was fondly called DBG by his well-wishers.

Desh Bandhu Gupta’s net worth was reported to be $3.6 billion at his death.

Manju Gupta

Manju Gupta is the Chairman of Lupin Limited. She is a graduate of Arts from the University of Delhi. Mrs. Gupta has been on the Board of Directors since its inception. She is credited for all the strategic decisions she took and her important contributions to making Lupin one of India’s top corporations. She is also the Chairman of the Corporate Social Responsibility (CSR) Committee.

Vinita D. Gupta

Vinita D. Gupta is the eldest daughter of Desh Bandhu Gupta and Manju Gupta. Presently, she is the Chief Executive Officer of Lupin Limited and the chairperson of Lupin Inc (LI), and its US subsidiary, Lupin Pharmaceuticals Inc (LPI).

Vinita Gupta did her bachelor’s degree in Pharmacy from the University of Mumbai. She also has an MBA degree from the Kellogg School of Management at Northwestern University, Illinois. When Vinita was the chairman and CEO of Lupin Pharmaceuticals Inc from 2003 to 2013, she extended the US business from 5% to over 45% of Lupin’s overall revenue. She joined Intrexon, an American Biotechnology company, as a non-executive director in April 2017.

Along with her brother Nilesh Gupta, the MD of Lupin was awarded Ernst & Young Entrepreneurs of the Year for India in 2015. She also received the Forbes India Leadership Awards 2016 – Entrepreneur of the Year. In 2014, Forbes Asia named her one of the Top 50 Power Businesswomen in the Asia Pacific. Vinita was voted Outstanding Business Woman Leader of the Year and inducted into the Hall of Fame as Most Powerful Women in Business 2016.

Vinita D. Gupta is married to Brij Sharma, a rich investor, and entrepreneur from the United States. They have a son named Krish Sharma and live in Florida.

Nilesh D. Gupta

Born in 1974, Nilesh d. Gupta, the only son of Desh Bandhu Gupta, is the Managing Director of Lupin Limited since September 2013. His key responsibility is in charge of the research, supply chain, production, quality, and regulatory activities of the company.

Nilesh D. Gupta holds a bachelor’s degree in chemical engineering from the University Department of Chemical Technology in Mumbai. He also earned his MBA in 2002 from the Wharton School at the University of Pennsylvania in the United States, where he focused on healthcare, strategic management, and finance.

In addition to winning the Ernst & Young Entrepreneur of the Year Award for India in 2015, Nilesh Gupta and his sister Vinita Gupta, the CEO of Lupin, were named “Entrepreneurs of the Year” at the Forbes India Leadership Awards in 2016.

Nilesh D. Gupta’s wife’s name is Shefali Nath Gupta, and they have a son and a daughter together.

Lupin Limited – Startup Story

In 1968, Lupin commenced its first business. Desh Bandhu Gupta borrowed Rs 5000 from his wife to establish Lupin. In the initial days, the company had only two employees; a peon and a typist. Gradually, the firm was able to launch its production plant for making folic acid and iron tablets for the Government of India’s mother and child health program after receiving additional funds from the Central Bank of India.

In 1979, the company established the first formulations facility and research and development center in Aurangabad, India. In 1987, Lupin’s Cephalexin facility in Mandideep (Madhya Pradesh) and seven ADCA plants went online. Afterward, Lupin began producing anti-TB pharmaceuticals, which at one point accounted for 36% of the company’s revenues and made it the largest producer of TB medications in the world.

With the rise in the success of Lupin, Lupin Human Welfare and Research Foundation were established by Desh Bandhu Gupta (LHWRF) in 1888. LHWRF is an initiative to elevate poor communities in India through social development activities. This initiative was established long before CSR spending became a part of corporate vernacular.

In 1989, through a joint venture, Lupin Chemicals (Thailand) Ltd. was created in Thailand, and the Ankleshwar and Mandideep factories were given U.S. FDA permits. In 2001, Lupin Research Park, a cutting-edge R&D facility, was opened in Pune, India.

It was in 2003, the United States-based trade, marketing, and development company Lupin Pharmaceuticals Inc. was established. Around 2006, Lupin announced its initial issuance of $100 million worth of Foreign Currency Convertible Bonds (FCCB), which will be listed on the Singapore Stock Exchange. After two years, there was the expansion of the product line at Japan-Kyowa through the Ministry of Health and Labour Welfare’s approval of 10 goods.

Since then, Lupin acquired many companies to strengthen its business operations. In 2012, Lupin was included in the NIFTY 50 Index.

Lupin opened a new facility in India’s Visakhapatnam and a new plant in Tottori, Japan in 2016. After one year, Desh Bandhu Gupta, the company’s founder, passed away in June 2017 and was succeeded as chairman by his wife, Manju Deshbandhu Gupta.

As of today, Lupin has a market capitalization of $ 3.6 billion and is among the top 10 largest generic pharmaceutical companies globally.

Lupin Limited – Mission and Vision

The mission statement of Lupin is, “To become a transnational pharmaceutical company through the development and introduction of a wide portfolio of branded and generic products in key markets.”

The company aims to consistently produce high-quality and innovative products that are solely focused to improve the healthcare sector.

The core values that define Lupin are:
- Integrity
- Teamwork
- Passion for Excellence
- Customer Focus
- Respect & Care
- Entrepreneurial Spirit
Lupin Limited – Name, Tagline, Logo

Lupin’s Logo

Desh Bandhu Gupta was inspired by the ‘Lupin flower‘ for which he named the company after it. The Lupin flower is said that it can grow even in harsh conditions and can also nourish the soil at the same time. The flower’s ability of unselfish giving and resiliency is what roused Desh Bandhu Gupta to provide quality medical needs to people.

The tagline of Lupin reads, “Research Driven. Quality Committed. Customer Focused.”

Lupin Limited – Business Model

The business operations of Lupin cover the whole pharmaceutical value chain, from biotechnology to branded and generic formulations, APIs, biosimilars, specialty drugs, therapeutic areas, and cutting-edge drug delivery technologies. It has produced over 10,000 products till now.

With the creation of medications for the treatment of multi-drug resistant (MDR) tuberculosis, Lupin continues to improve its anti-TB portfolio as the market leader in the anti-tuberculosis market.

The three main business segments of Lupin are:

Anti-Tuberculosis

As mentioned earlier, Lupin is a global leader in Cephalosporins, Cardiovascular, and the anti-TB space. Through GDF procurement, Lupin’s business supplies its formulations to more than 50 countries as a strategic provider of anti-TB drugs to the Stop TB Partnership, a global initiative established in 2001 to end tuberculosis as a public health issue.

The top-selling anti-TB compounds from the corporation include ethambutol, rifampicin, and pyrazinamide.

Diagnostics Business

The previous year, in 2021, Lupin entered the diagnostics market. The company has announced to offer a wide variety of diagnostic tests in India, which include molecular diagnostics, cytogenetics, flow cytometry, microbiology, and serology.

Lupin Biotechnology Research Group

Based in Pune, the Lupin Biotechnology Research Group focuses on developing biosimilars. It provides capabilities for product development including clone development, process optimization, analytical method development, bioassay, formulation, stability studies, and non-clinical and clinical studies, all supported by a solid understanding of regulatory and IP issues. To name a few biosimilar products developed by Lupin are – Etanercept, Filgrastim, Peg-filgrastim, and Ranibizumab.

Lupin’s business in India, which they call India Region Formulations (IRF) business focuses notably on Chronic illness therapy areas like Cardiology, the Central Nervous System (CNS), Diabetes, Anti-Asthma, Anti-Infective, Gastro Intestinal, and Oncology, and Lifestyle disorders. It operates its business in 12 manufacturing facilities in India, including those in Jammu (J&K), Mandideep & Indore (Madhya Pradesh), Ankaleswar & Dabasa (Gujarat), Tarapur, Aurangabad, and Nagpur (Maharashtra), Goa, Visakhapatnam (Andhra Pradesh), and Sikkim. It has two research facilities located in Pune and Aurangabad.

The corporation sells its medications in 70 different countries, with a presence that includes developed markets like;

United States

Lupin US Division

Out of the 77 items sold in the US generics market, the firm is the market leader in 28 of them, and it is in the top three by market share for 57 of them (IMS Health, December 2014): A pediatric antibiotic called Suprax (Cefixime) is Lupin’s best-selling item in this region.

Europe

The areas of business for Lupin in the European Union include CNS, Cardiovascular, and Anti-Infectives therapies, as well as specialized potential in fields like ophthalmology, dermatology, and oral contraceptives. The company operates its business in Germany through its acquisition of Hormosan Pharma GmbH. Its business in the UK is a direct-market deal.

Japan

In Japan, Lupin is one of the Top 10 players in generic medicines. Through its subsidiaries, Kyowa Pharmaceutical Industry Co. Ltd. (Kyowa), and I’rom, Pharmaceutical Co. Ltd (IP), Lupin does business in Japan.

Australia

Lupin does business with the help of its subsidiary Generic Health Pte. Ltd. (GH).

South Africa

Lupin South Africa’s business dominates the Cardiovascular sector and is expanding in the Neurology, Gastroenterology, and Over-The-Counter (OTC) markets. The company has a variety of wellness initiatives to assist patients in achieving holistic well-being.

Philippines

Multicare Pharmaceuticals (Multicare), a branded generic firm with a focus on women’s health, pediatrics, gastro-intestinal care, and diabetes care, is a subsidiary of Lupin in the Philippines. Its other focus area also includes – rheumatology, respiratory, oncology, neuroscience, and nephrology.

Lupin’s business is also spread across Mexico and Brazil with focus areas in visual health, food supplements, respiratory diseases, algology, male health, and angiology.

Lupin’s Covid-19 Response

Lupin is said to be among the first of the few companies that offered its support in the fight against Covid-19. The company gave donations in form of money and other materials as a part of its Global Giving Programmes. It has contributed to PM Cares Fund, Launching the Jan Kovid helpline in Mumbai, Bhopal, Indore, and Pune. Furthermore, the company donated meals to frontline healthcare workers and delivered masks and PPE kits to various healthcare institutions in the USA.

Lupin Limited – Revenue Model

As of FY22, the total revenue of Lupin stood at $2.2 billion.

Lupin generates its maximum revenue from India around 38% of revenue, from North America – 36%, Growth Markets (Australia, Brazil, and Mexico)- 9%, EMEA (South Africa and EU)- 9%, and the Rest of the World – 2%. It is also reported that it renders 6% of its revenue through APIs and anti-TB business.

Lupin Limited – Funding and Investors

Baring Private Equity India provided funds to Lupin in Post-IPO Equity round on September 1, 2013. However, the details of the total funds raised by Lupin are undisclosed.

Lupin Limited – Mergers and Acquisitions

Till now, Lupin has purchased nine different businesses. Southern Cross Pharma, a privately held corporation that supplies pharmaceutical items to the Australian and New Zealand markets, was their most recent purchase as of July 30, 2021.

Date Acquiree name

January 19, 2018 Bio-Pharm

August 1, 2016 Glochem – manufacturing unit

May 5, 2015 ZYG Pharma

December 13, 2013 Elder Pharmaceuticals

June 27, 2005 Excella GmbH

Lupin Limited – Advertisements and Social Media Campaigns

In 2022, Lupin came up with the campaign #BanoKhudSeBehetar to promote its 100% Ayurvedic Energy and Immunity capsules. The ad features Bollywood actor, Hrithik Roshan.

Here’s what Anil Kaushal, Head of OTC Business, Lupin, said about the campaign, “In today’s highly demanding times, a product like ‘Be One’ is only increasing in relevance. The consumer today is looking to constantly better themselves and this is where ‘Be One’ comes in as a motivator to ensure they have the energy and health needed in this journey.”

During the pandemic time, Lupin launched a campaign with the #BeSafeWithLupiSafe to promote its newly designed hand sanitizer wipes called LupiSafe Wipes. The firm, Contract Advertising, a Wunderman Thompson Group affiliate and a participant in the WPP network, was entrusted with proving the effectiveness of the recently launched germ-kill wipes. The said campaign was introduced during the IPL with a collection of 4 short films for TV and social media channels to improve attention.

Lupin Limited – Awards and Achievements

The list of awards and achievements won by Lupin are:
- Lupin has won the prestigious ATD (Association of Talent Development) BEST Award
- Lupin has earned recognition at the 5th Edition of the Global CX Summit, India, for the Joint Airway Initiative (JAI)
- Lupin was Named Among the ‘Factories of the Future at the Economic Times Promising Plant Awards 2022
- Lupin’s Pithampur team won two awards- 1 Platinum, and 1 Gold at the CII National Technology Competition
- Lupin has won the Bioprocessing Excellence in South Asia Award at the prestigious Asia Pacific Bioprocessing Excellence Awards 2022 by IMAPAC
- Lupin’s corporate communication team was named among the Top 30 Corporate Communications Teams for 2022 by Reputation Today
- Lupin won the ‘Digital Pharma Marketing Excellence Award’ for ‘Leveraging Technology for Patient Care at the 6th Edition of DIGIPHARMAX Conclave on Emerging Health Trends in Pharma Digital Marketing & Awards 2022
- Lupin was awarded Marketing Campaign Of The Year by ET India Pharmaworld Awards for its Awareness, Screening, and Treatment (AST) Campaign
- Lupin won Businessworld’s Diversity and Inclusion Award 2022 for “Outstanding Diversity Network”
Lupin Limited – Competitors

The top competitors of Lupin Limited are:
1. Sun Pharma
2. Divi’s Laboratories
3. Dr. Reddy’s Laboratories
4. Cipla
5. Aurobindo Pharma
6. Apollo Hospitals
7. Abbott India
8. Biocon Limited
9. Torrent Pharma
10. Gland Pharmaceuticals
11. Alkem Laboratories
Lupin Limited – Future Plans

The company is planning to enter the Chinese market to compete with its rivals, Sun Pharmaceuticals, and Dr. Reddy’s Labs. Some of its products are waiting to be approved by China.

Lupin also has many new products lined up, which are soon going to be launched in the US. The company is aggressively working on respiratory products.

FAQs

Who is the CEO of Lupin?

Vinita D Gupta is the CEO of Lupin.

Where is the head office of Lupin?

The head office of Lupin is in Mumbai.

Is Lupin a Multinational Company?

Yes, Lupin is a multinational company based in India.

When did Lupin go public?

Lupin went public on June 24, 1993.
October 19, 2022

Headquarters	Mumbai
Type	Private
Founder	Desh Bandhu Gupta
Founded	1968
Revenue	15299.25 Crores- (FY2020-21)
Website	www.lupin.com

Biophar Lifesciences Pvt. Ltd. | Success Story of becoming India’s top producer of pharma formulations

We are aware that the Indian pharmaceutical industry is a significant player because it is the largest supplier of generic medications. The road ahead for medicine spending in India is only going upwards. The PCD pharma franchise business, which is like a large pool of all pharma dealers, and manufacturers in one place are responsible for the upliftment of the pharmaceutical industry.

Biophar Lifesciences, founded in 2004 by Gulshan Rawat, is among the industry’s top producers and marketers of pharmaceutical formulations because of its capacity to produce, export, and provide a wide array of high-quality injectables, capsules, tablets, general products, soft gel capsules, dry syrup, syrup, ointments, eye drops, ear drops, creams, beta-lactam products, nutraceuticals, soaps, external liquids, lotion, facewash.

Biophar Lifesciences – Company Highlights
Biophar Lifesciences – About
Biophar Lifesciences – Industry details
Biophar Lifesciences – Founder
Biophar Lifesciences – Mission and Vision
Biophar Lifesciences – Name, Tagline, Logo
Biophar Lifesciences – Business & Revenue Model
Biophar Lifesciences – Awards and Achievements
Biophar Lifesciences – Competitors
Biophar Lifesciences – Future Plans

Biophar Lifesciences – Company Highlights

Headquarters	Chandigarh, India
Sector	Pharmaceutical Manufacturing
Type	Private
Founder	Gulshan Rawat
Founded	2004
Revenue	Rs 10-25 crores (approximately)
Website	www.biophargroup.com

Biophar Lifesciences – About

Biophar Lifesciences is a Chandigarh-based pharmaceutical company that is engaged in the manufacturing of various pharma products and PCD pharma franchise business.

The company is mostly engaged in pharmaceutical formulations manufacturing, marketing, and export-focused business. This business area is expanding widely and quickly.

Biophar Lifesciences has a strong R&D section that allows them to stay on top of the most recent developments in the market. Their group of researchers works painstakingly on several research projects to enhance the production and efficacy of its selection of pharmaceutical drugs.

One of India’s leading third-party manufacturing enterprises is Biophar Lifesciences. It can offer all types of medicine ranges, including pellets, tablets, capsules, herbal nutraceuticals, protein powder, gym supplements, capsules, tablets, and pharma sachets, due to its large-scale production facility.

Biophar Lifesciences has the following subsidiaries:

Cagrus Biopharma
Biovxia Pharma
Medivaxia Pharma
Pharvax Biosciences
Rech Elist Pharma
Zesmed Pharma
Mediflower Pharma

Biophar Lifesciences – Industry details

As per reports, the market value of the pharmaceutical industry was $42 billion in 2021. This value is going to increase and is expected to reach somewhere around $120-130 billion by 2030.

Biophar Lifesciences – Founder

Biophar Lifesciences is founded by Gulshan Rawat in 2004.

Gulshan Rawat

Gulshan Rawat is presently the Managing Director of Biophar Lifesciences Pvt. Ltd. He has more than 16 years of experience in the pharma industry.

Biophar Lifesciences – Mission and Vision

Biophar Lifesciences’s mission statement is, “To achieve worldwide recognition as a supplier of superior quality herbal and pharmaceutical products.”

Biophar Lifesciences aims to supply the best quality pharma products and collaborate with new businesses to offer the best services.

The vision of Biophar Lifesciences is, “Simplify business model in the pharma industry, deliver more innovative and a number of products. Grow a diversified business in India and across the world.”

Biophar Lifesciences – Name, Tagline, Logo

Biophar Lifesciences – Business & Revenue Model

The business operations of Biophar Lifesciences are manufacturing, producing, and marketing pharmaceutical formulations with a diversified product portfolio. The company also deals in the PCD Pharma Franchise business. Due to years of experience, it can provide a variety of Soft gels, Capsules, Tablets, and Syrups. Biophar’s pharmaceutical goods are created using high-quality ingredients that come from reputable suppliers that have ISO certification and GMP compliance units.

Its manufacturing unit is named Tanishka Pharmaceutical and is well-equipped with the latest machinery with a team of experts who offer quality pharma products. Its manufacturing unit is situated in Solan, Himachal Pradesh.

Biophar Lifesciences also operates as a third-party pharma manufacturer. From product development through production, packaging, and the creation of marketing materials, it provides comprehensive solutions. It manufactures and packages ready-to-market goods, including liquid syrups, dry syrups, injections, soft gelatin capsules, sachets, and capsules.

Through third manufacturing services, the company generates the maximum number of its revenue.

PCD Pharma Franchise Business of Biophar spreads across almost all the major regions of the country. It currently has more than 250 associates in its franchise business.

The company claims that it has its quality assurance team to make sure that the pharma products are tested at every step of the manufacturing process till their packaging. It also offers monopoly rights to a selected number of business areas. These monopoly rights give Biophar Lifesciences the liberty to achieve good revenue that benefits its associates in a better way.

Biophar Lifesciences – Awards and Achievements

The list of awards and certifications of Biophar Lifesciences are:

Biophar Lifesciences has been recognized by Indiamart for the Trustseal award – 2014
Biophar Lifesciences is an ISO 9001:2008 & GMP certified company

Biophar Lifesciences – Competitors

Biophar Lifesciences competes with the following pharma companies

Sun Pharmaceuticals Pvt. Ltd.
Cipla Limited
Dr. Reddy’s Laboratories
Aurobindo Pharma Ltd.
Lupin Ltd.
Glenmark Pharma Ltd.
Torrent Pharma
Zydus Lifesciences Ltd.
Innovexia Life Sciences Pvt. Ltd.
Abbott India
Gland Pharma Ltd.

Biophar Lifesciences – Future Plans

Biophar Lifesciences has some upcoming projects in the coming months. It is soon launching new products in pharmacological & therapeutical areas. Some of the products are in categories like – alkalizer, anti-biotic, anti-cold, hepatology, malt, menstrual abnormalities, fever, and many more.

FAQs

Who heads Biophar Lifesciences?

Biopher Lifesciences is headed by Mr. Gulshan Rawat, the MD of the company.

Where is the headquarter of Biopher Lifesciences?

Biophar Lifesciences has its headquarters in Panchkula, Haryana.

How many subsidiaries does Biopher Lifesciences have?

Biopher Lifesciences has 7 subsidiaries.

Is Biopher Lifesciences a private company?

Yes. Biopher Lifesciences is a privately held company.

October 17, 2022

Divi’s Laboratories | Journey of Divi to become India’s second most valuable pharma company

Medicines, or drugs, or tablets, cough syrups, or pills, have become a part of our everyday lives. Have you ever thought about what would have happened if medicines were never discovered? Scary to think, right? because how else we would survive without treating different illnesses, or diseases?

Things were very different before 1800 as to how humans used to treat and prevent diseases. Although it’s tough to put so much information in one go, we can say that the first pharmaceutical medication was produced in 1804 by Friedrich Sertürner, a German scientist.

The establishments and inventions with curious methods of preventing many diseases provoked a lot of discoveries. As a result, the pharma industry was born with a lot of organizations indulging in manufacturing and producing drugs and medicines.

Divi’s Laboratories with its headquarters in Hyderabad is an Indian global Pharmaceuticals company founded in 1990 by Dr. Murali Krishna Prasad Divi. The company is regarded as one of the top pharmaceutical companies for ‘custom synthesis’ and also as India’s second most valuable pharma company.

Want to know what makes the company a custom manufacturer? then please do give a read to this article, where we cover details of Divi’s Laboratories’ success journey, who are its founders, its mission & vision, products and services offered by Divi’s Lab, its business and revenue model, what are its plans for the upcoming future and much more interesting information.

Divi’s Laboratories – Company Highlights

Headquarters	Hyderabad, India
Sector	Pharmaceuticals
Type	Public
Founder	Divi Murali Krishna Prasad
Key People	Satchandra Kiran Divi (CEO)
Founded	1990
Revenue	$1.2 billion (2022)
Subsidiaries	Divis Laboratories (USA) Inc, Divi’s Laboratories Europe AG, Divi’s Nutraceuticals
Website	divislabs.com

About Divi’s Laboratories

Standing tall since 1990, Divi’s Laboratories is India’s second pharma company by market capitalization touching nearly $17 billion in 2021. It is one of the leading pharmaceutical companies in the world that is engaged in manufacturing Active Pharmaceutical Ingredients (APIs), Intermediates, and Nutraceuticals. The Hyderabad-based pharma company is also recognized as a Reliable Supplier of generic APIs and Custom manufacturers to Big Pharma.

The company has two subsidiary brands namely:

Divi’s Laboratories (USA) Inc -located in New Jersey, USA
Divi’s Laboratories Europe AG – Basel, Switzerland

Divi’s Laboratories has three manufacturing units located near Hyderabad and Visakhapatnam in India, and three R&D centers with more than 400 scientists and 42 patents across India. As the company is the world’s leading manufacturer of APIs, Intermediates, and Registered Starting Materials, it also provides high-quality goods with the greatest degree of compliance and virtue to more than 100 countries. Divi’s Laboratories was listed as a public limited business on the Indian stock exchange.

The manufacturing zones of Divi’s laboratories have been audited by authorities such as Regulatory Authorities, several Big Pharma/Multinational Companies, Statutory Authorities, and Global Environmental, Health, and Safety teams. On top of that, agencies such as USFDA, EU GMP (UK, Slovenia, German, and Irish authorities), HEALTH CANADA, TGA, ANVISA, COFEPRIS, PMDA, and MFDS keep have all visiting its advanced manufacturing plants in Hyderabad and Vizag for inspection.

One of the most recent achievements of Divi’s is the distinction of being one of the top three API manufacturers in the globe, as well as one of the top API firms in Hyderabad. Divi’s Lab claims to have more than 17,000 trained people who work tirelessly to make the company the leading pharma company in India.

Divi’s Laboratories – Industry details

According to experts, the global pharmaceuticals manufacturing industry is predicted to expand at a compound annual growth rate (CAGR) of 11.34% from 2021 to 2028. The Indian pharmaceutical sector is expected to be worth US$ 49 billion in FY22, representing a 9% increase over FY21.

The introduction of new technologies and efficient manufacturing types of equipment has transformed this industry massively following which, the industry is only expected to grow positively to newer heights. India is the largest contributor to exports, followed by North America, African countries, and Europe.

Divi’s Laboratories – Founder and Team

The founder of one of the leading APIs manufacturer companies, Divi’s Laboratories, is Dr. Divi Murali Krishna Prasad.

Divi Murali Krishna Prasad

Dr. Divi Murali K. Prasad was born in a small village in Andhra Pradesh. He was the youngest among his twelve other siblings.

Dr. Divi Murali is a graduate of the Manipal College of Pharmaceutical Sciences with a degree in Bachelor of Pharmacy. His career started by working at Warners Hindustan Company. While working at Warners, Dr. Divi Murali left for America with his family during 1976-77 in search of better opportunities. Dr. Divi Murali’s entrepreneurial journey began in 1984 after he came to India after working in key research and development positions at American companies such as Fike Chemical.

Upon returning to India, Dr. Divi Murali met Dr. Anji Reddy, the founder of Dr. Reddy’s Laboratories, with whom he bought a company called ‘Keminar’. Eventually, with the experience and knowledge, Dr. Divi Murali had gained, he finally founded his own company, Divi’s Laboratories in 1990.

Presently, Dr. Divi Murali Krishan Prasad is the Chairman and Managing Director of Divi’s Laboratories. He is also a member of the American Institute of Chemical Engineers, American Chemical Society, and American Cosmetic Society. He was listed as the 45th wealthiest man in India in 2013 as Forbes listing. Furthermore, he was featured in Hurun India Rich List 2021 with a net worth of ₹79,000 crores making him the 14th richest person in India.

Dr. Satchandra Kiran Divi

Commonly known as Kiran Divi is the Whole-time Director & Chief Executive Officer of Divi’s Laboratories. Dr. Kiran Divi is the son of Dr. Murali Divi. He is also the youngest billionaire in the Telugu States with a stake of 20.34% in Divi’s Labs. Dr. Kiran Divi holds a bachelor’s degree in Pharmacy from Mangalore University and a master’s degree from Jawaharlal Nehru Technological University. Along with this, Dr. Kiran Divi achieved a doctorate from the Gitam Institute of Technology and Management. He is married to Shakuntala Divi. The pharma company has been producing high-quality company strategies and plans under his guidance, guaranteeing alignment with both short and long-term objectives.

Nilima Prasad Divi

Nilima Prasad Divi is the Whole-Time Director (Commercial) of Divi’s Labs. She holds a master’s degree in International Finance from the University of Glasgow, UK. She oversees Material Sourcing & Procurement, Corporate Finance, and Investor Relations.

Ms, Nilima owns a stake of 20.34% in Divi’s Laboratories, which makes her a billionaire woman and also the richest woman in the Telugu States. Ms. Nilima also manages the company’s Material Sourcing & Procurement, Corporate Finance, and Investor Relations. Ms. Nilima developed substantial business acumen and knowledge with material need planning and finance before joining Divi’s.

Divi’s Laboratories – Startup Story

Divi’s Labs started as a Research & Development Centre as its core area in 1990. It grew and concentrated on inventing novel processes for the manufacturing of Active Pharmaceutical Ingredients (APIs) and Intermediates, as well as delivering comprehensive turnkey solutions and advising to the local pharmaceutical sector. Divi’s Laboratories’ brand name was changed from Divi’s Research Centre in 1994. Later after, in 1995, the business opened its first manufacturing facility in Choutuppal, Telangana. Its second production plant, located near Visakhapatnam, began operations in 2002.

On February 17, 2003, Divi’s Labs went public with an initial public offering (IPO). In 2007, the pharma company set up a Nutraceuticals facility at its Manufacturing Unit 2, near Vishakhapatnam. After a few years, the organization opened a research center in Hyderabad in 2010. Today, the company is a leader in producing one of the highest quality APIs and other drugs and medicines.

Divi’s Laboratories – Mission and Vision

The vision statement of Divi’s Laboratories is, “To create value for all stakeholders by manufacturing high-quality Generic APIs, Custom synthesis of APIs & Intermediates along with Nutraceutical Ingredients to the Global Pharmaceutical & Nutraceutical industry through sustainable leadership in chemistry.” The company aims to add some significance in the area of manufacturing through its core values and serving society in general.

Its mission is, “To be a responsible business, adding value through our core competency in the area of chemistry while adhering to our core values and serving the immediate community and at large through our diverse social initiatives that would establish a strong foundation for a better tomorrow for all stakeholders.”

Divi’s Laboratories consists of five core business values:

Financial Stability
Reliable Supply Partner
Trustworthy
Transparency
Complimentary

Divi’s Laboratories – Name, Tagline, Logo

The name of the company is after the founder Dr. Murali Divi’s family name, ‘Divi’.

The tagline of Divi’s Laboratories is, “Striving for leadership through chemistry”.

Divi’s Laboratories – Business Model

The business model of Divi’s Laboratories operates on a B2B model.

Its business mostly engages in export markets and features a diverse product portfolio that includes generics APIs and bespoke synthesis. The company includes World-class production facilities with a total capacity of 14000 m3, one of which is the world’s largest API manufacturing plant. It has three major manufacturing units near Hyderabad and Visakhapatnam. Two huge cGMP API manufacturing machines produce thousands of tonnes of APIs that are sold to over 100 countries.

With its motto, “Delivering a product with a value proposition, throughout the life-cycle of the product“, Divi’s Laboratories have about 400 best-in-class scientists working in their three R&D facilities across India. DRCs, Divi’s Labs Research Centres are located in Sanath Nagar, Hyderabad, while Process Development & Support Centres (PDSCs) are located at the production locations.

There are more than 2000 employees who are assigned to Divi’s Labs Quality Assurance and Quality Control. These employees are dedicated to upholding the highest quality standards in cGMP production through frequent assessments and ongoing development of the Quality Management System. As mentioned earlier, all the manufacturing facilities are fully inspected regularly by top health agencies such as the FDA, EU GMP, HEALTH CANADA, TGA, ANVISA, COFEPRIS, PMDA, and MFDS.

Generic APIs products

The pharma company is a global pioneer in High Volume Generic APIs. The product list contains a highly selected 30 APIs that are commercially made in batches of tens to hundreds to thousands of Tonnes per year, thus making it the world’s largest API manufacturer.

To name a few generic APIs products, these are Bupropion HCl, Diltiazem HCl, Gabapentin, Levetiracetam, Capecitabine, Nabumetone, Pregabalin, Quetiapine Fumarate, Valsartan, Triprolidine HCl, and many more. Some of these products are regulated by other countries like Australia, Singapore, Saudi, China, Thailand, Korea, EU Countries, and Taiwan among others.

The company is currently developing new eight products in the therapeutic categories such as – anti-diabetic, anti-viral, anti-hypertension, anti-coagulant, etc.

Custom Synthesis

Divi’s Laboratories is also engaged in the business of manufacturing customized synthesis, which means it offers its manufacturing services on a contract basis for many global pharma companies. It has established relationships with 6 of the top 10 Big Pharma.

Nutraceuticals

Located at its Unit II manufacturing location, the Nutraceutical Facility by Divi’s is an integrated facility for the synthesis of active ingredients as well as final forms of carotenoids. It is one of the world’s leading producers of Carotenoids. The facility contains a full-service R&D, application testing, and support center. Divi’s Laboratories’ nutraceutical product line includes a complete spectrum of carotenoids such as Beta Carotene, Astaxanthin, Lycopene, Canthaxanthin, and Canthaxanthin, as well as additional completed forms such as Lutein and Vitamins, these include A, D3, D2, E Acetate, and A Palmitate. This high-quality carotenoid and vitamin components by Divi’s are used by many food & beverage, nutritional supplement, pet food, and feed sectors.

Divi’s Laboratories CSR & Sustainability activities

Since its inception, Divi’s has concentrated on various corporate social responsibility initiatives, affecting the lives of thousands of people living in and around Andhra Pradesh and Telangana. Its CSR initiatives include promoting education, empowering women, rural development, preventive health care, safe drinking water, animal welfare, and raising the living standards of community members.

So far, Divi’s Laboratories have empowered more than 22,000 children by building around 206 schools and providing around 92 safe drinking water to more than 2,41,000 people in villages. Alongside, the company has executed more than 1,36,000 plantation drives in 35 villages, and more.

The company has distributed Study material to 10th-grade students across the government schools in Andhra Pradesh, distributed Horlicks Sachets to 180 schools, and donated dual desk benches to Government schools. It has also dedicated its efforts to improving the lives of many villagers in Panthangi village in Telangana and Chippada village in Andhra Pradesh through its Model Village Project.

Divi’s Laboratories has also dedicated itself to a sustainable environment by launching various sustainable initiatives like Water Management (installed new Sewage Treatment Plants (STPs) at manufacturing sites aided in the saving of 1,22,400 M3 of water) Energy Management (Installed advanced and energy efficient equipment – 1,08,79,000 KWH), and Waste Management (solvent recovery stations were established to recover and reuse solvents)

Their CSR activities don’t end there. Besides, over 33,550 EHS training sessions were conducted, with 3,30,900 participants.

Divi’s Laboratories Covid-19 Response

In response to the pandemic, the company has been very quick to implement tight measures at its sites. Divi’s has been checking all of its business processes and production schedules, prioritizing activities of significance such as making sure appropriate behavior of its employees following all safety and sanitation protocols and ensuring its supply chain’s engagement with vendors and customers. Even though there were certain pitfalls, in the beginning, it has been able to sustain its business operations and assure an ongoing supply of active pharmaceutical ingredients to clients for the manufacture of important medications. The pharma company has also begun to vaccinate its employees and their dependents.

Divi’s Laboratories – Revenue Model & Growth

For Fiscal Year 2021-22, Divi’s Laboratories has been able to achieve another year of decent business growth and profitability. As the company is primarily engaged in the export market, the exports accounted for 90% of total sales income, and 77% of commerce was conducted in cosmopolitan markets such as Europe and America. The Rest of the World accounted for 4.0%, Asia for 9.2%, and India accounted for 10.0%.

The company made a revenue of $1.2 billion in 2022. It claims to have a revenue growth of 31%.

Revenue Distribution of Divi’s Laboratories

Divi’s Laboratories – Shareholdings

Divi’s Laboratories is a publicly listed company with its IPO in 2003. Its ISIN code is INE361B01024. The company has been funded by many fund managers. Some of the important ones have been highlighted in the following list:

Fund Name	Fund Manager	Shares in %
SBI Equity Hybrid Fund-Reg(G)	R. Srinivasan	2.89
Axis Long Term Equity Fund-Reg(G) Jinesh Gopani	4.60
SBI BlueChip Fund-Reg(G)	Sohini Andani	2.92
SBI Nifty 50 ETF	Raviprakash Sharma	0.65
Axis Bluechip Fund-Reg(G)	Shreyash Devalkar	1.90
UTI Flexi Cap Fund-Reg(G)	Ajay Tyagi	1.39
Nippon India Pharma Fund(G)	Sailesh Raj Bhan	7.47
UTI Nifty 50 ETF	Sharwan Kumar Goyal	0.65
Axis Growth Opp Fund-Reg(G)	Jinesh Gopani	2.25
Aditya Birla SL Equity Hybrid 95 Fund(G)	Satyabrata Mohanty	1.70
Aditya Birla SL Pure Value Fund(G)	Milind Bafna	3.19
SBI Healthcare Opp Fund-Reg(G)	Tanmaya Desai	6.89
UTI Mastershare-Reg(G)	Swati Kulkarni	1.12
SBI Magnum Equity ESG Fund-Reg(G)	Rohit Shimpi	2.12
Sundaram Large and Mid Cap Fund(G)	Ravi Gopalakrishnan	1.43
Aditya Birla SL Pharma & Healthcare Fund-Reg(G)	Dhaval Shah	6.62
Edelweiss Nifty 100 Quality 30 Index Fund-Reg(G)	Bhavesh Jain	3.04
Motilal Oswal S&P BSE Healthcare ETF	Swapnil P Mayekar	8.18
Axis NIFTY Healthcare ETF	Jinesh Gopani	10.58
Aditya Birla SL Nifty Healthcare ETF	Lovelish Solanki	10.59

Divi’s Laboratories – Awards and Achievements

Divi’s Laboratories has been a continuous recipient of many prestigious awards for its manufacturing, CSR, and sustainability activities. Here’s a list of awards achieved by the company in recent years:

2022

Divi’s received the EHS excellence Award by CII South Region

2021

Lifetime Achievement Award by ICON SWM
Lifetime Achievement Award for significant contribution to the circular economy and waste management by International Society of Waste Management, Air & Water (ISWMAW)
Divi’s received the CII-SR EHS Excellence Award 2020 – “4 Star Rating” for commitment to EHS practices
It has received India’s most prestigious Safety Award ‘Suraksha Puraskar Award for the year 2021 from theNational Safety Council of India (NSCI)

2020

Achieved the Prashansa Patra – NSCI Safety Awards -2020 from the National Safety Council of India (NSCI)

2019

Divi’s was recognized as the Best Partner – Smart Village Smart Ward by Andhra Pradesh State Government
CII EHS Excellence Awards 2019 – 3 star rating by the Confederation of Indian Industry (CII)
Divi’s Labs was recognized as the 2019 HURUN Self-made Philanthropist of the Year as per Hurun Report

2018

Divi’s Labs achieved IconSWM (International Conference on Sustainable Waste Management) by the International Society of Waste Management, Air & Water
Achieved the May Day award for Best Management Department of Labour, Government of Andhra Pradesh

Divi’s Laboratories – Competitors

The top competitors of Divi’s Laboratories are:

Dr. Reddy’s Laboratories
Sun Pharmaceuticals Pvt. Ltd.
Cipla Limited
Abbott India
Torrent Pharma
Alkem Lab
Pfizer
Aurobindo Pharma Ltd.
Zydus Lifesciences Ltd.
Lupin Ltd.
Gland Pharma Ltd.
Ajanta Pharma
Glenmark Pharma Ltd.
P&G

Divi’s Laboratories – Future Plans

The company aims to expand its capacity in producing more specialized APIs to the changing marketing conditions. As the leading pharma company for manufacturing customized APIs, it further wants to expand by seeking to hit a market size of $20 billion in molecules going off-patent during FY23–25.

FAQs

Who owns Divi Labs?

Divi Murali Krishna Prasad is the owner of Divi Labs.

What is the full form of API in pharma?

In pharma, API stands for Active Pharmaceutical Ingredient.

Is Divi an MNC?

Yes, Divi Labs is an MNC from India.

Where is Divi Labs based?

Divi Labs is based in Hyderabad.

October 11, 2022